var title_f32_57_33680="Sulfacetamide: Drug information";
var content_f32_57_33680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfacetamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/61/32723?source=see_link\">",
"       Sulfacetamide (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/42/26276?source=see_link\">",
"       Sulfacetamide (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9958 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-AFC96612BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33680=[""].join("\n");
var outline_f32_57_33680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/61/32723?source=related_link\">",
"      Sulfacetamide (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/42/26276?source=related_link\">",
"      Sulfacetamide (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33681="Rheumatoid pleural disease CT scan";
var content_f32_57_33681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatoid pleural disease CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography demonstrates extensive thickening of the visceral pleura in a patient with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33681=[""].join("\n");
var outline_f32_57_33681=null;
var title_f32_57_33682="Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens";
var content_f32_57_33682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33682/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33682/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33682/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/57/33682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to improve the potency of antiretroviral therapy, several studies have been conducted comparing four versus the standard three-drug therapy strategy for initial treatment of HIV infection.",
"   </p>",
"   <p>",
"    This topic summarizes the three large trials of four- versus three-drug combination regimens for the treatment of HIV infection. Considerations for choosing specific antiretroviral medications and guidelines for use of combination therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ABBREVIATIONS USED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following abbreviations are used for HIV antiretroviral medications:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nucleoside analogs",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp;ZDV; or AZT",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    &nbsp; &nbsp; &nbsp; 3TC",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp;ddI",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp; d4T",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABC",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non-nucleoside reverse transcriptase inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;EFV",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; &nbsp; NFV",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NELFINAVIR PLUS EFAVIRENZ PLUS NRTIS (ACTG 384)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTG 384 was a six-arm study comparing different strategies for initial therapy of HIV. Nine hundred eighty treatment-na&iuml;ve patients were enrolled. Among the comparisons included a four-drug, three-class regimen containing NFV 1250 mg twice daily plus EFV 600 mg daily plus two NRTIs with either NFV or EFV alone plus two NRTIs. The NRTIs used in this study were ZDV 300 mg twice daily plus 3TC 150 mg twice daily or ddI 400 mg daily plus d4T 40 mg twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a median follow-up of 2.3 years, the time to first virologic failure was longer with the four-drug regimen compared with",
"    <span class=\"nowrap\">",
"     NFV/ddI/d4T",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     EFV/ddI/d4T,",
"    </span>",
"    but importantly was not compared with",
"    <span class=\"nowrap\">",
"     EFV/ZDV/3TC.",
"    </span>",
"    The authors concluded that the triple combination of",
"    <span class=\"nowrap\">",
"     EFV/ZDV/3TC",
"    </span>",
"    was the preferred initial regimen for treatment-naive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFAVIRENZ VERSUS NELFINAVIR VERSUS BOTH (INITIO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open-label, randomized trial compared ART with two nucleoside analogs (ddI and d4T) plus either EFV or NFV or both (EFV plus NFV) in 911 treatment-naive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33682/abstract/2\">",
"     2",
"    </a>",
"    ]. The primary outcomes at the end of treatment were the proportion of patients with viral suppression and changes in CD4 count from baseline.",
"   </p>",
"   <p>",
"    At three years of follow-up, a significantly higher proportion of patients in the EFV group had a nondetectable viral load (74 percent) compared to the other two treatment groups (62 percent NFV; 62 percent NFV plus EFV). Patients in the EFV plus NFV group had a shorter time to a treatment-modifying adverse event and a shorter time to stopping their initial regimen than the other treatment groups.",
"   </p>",
"   <p>",
"    These results confirmed the virologic superiority of EFV-based versus NFV-based initial therapy for HIV infection. This study also demonstrated that use of all three drug classes as initial therapy is associated with a higher rate of toxicity with no added benefit.",
"   </p>",
"   <p>",
"    Similar to the ACTG trial, which also compared EFV, NFV, and EFV plus NFV, the INITIO trial found no difference between the three strategies in terms of immunologic benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ZIDOVUDINE/LAMIVUDINE/ABACAVIR/EFAVIRENZ (ACTG 5095)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double-blind, placebo-controlled trial (conducted from 2001 to 2005) randomly assigned 765 treatment-naive patients with a baseline HIV RNA level of 4.86 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and a CD4 count of 240 cells to receive EFV plus either coformulated",
"    <span class=\"nowrap\">",
"     ZDV/3TC",
"    </span>",
"    (eg, a three-drug regimen) or coformulated",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"      zidovudine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"      lamivudine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"      abacavir",
"     </a>",
"    </span>",
"    (eg, a four-drug regimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33682/abstract/3\">",
"     3",
"    </a>",
"    ]. The primary outcome measures were time to virologic failure and change in CD4 cell count.",
"   </p>",
"   <p>",
"    After a three-year follow-up, there were no significant differences between the standard three-drug versus four-drug regimens with regard to time to virologic failure, CD4 cell count responses, adverse events, or discontinuation rates. A subsequent subset analysis determined that neither pretreatment HIV RNA level nor pretreatment CD4 cell count were associated with an increased risk of virologic failure, even in patients with HIV RNA levels &gt;300,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or CD4 cell counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33682/abstract/4\">",
"     4",
"    </a>",
"    ]. The addition of ABC provided no additional benefit.",
"   </p>",
"   <p>",
"    This trial supports the current clinical guidelines that recommend two nucleoside analogs (with one of them 3TC or FTC) plus EFV for the initial treatment of HIV infection in treatment-naive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical trials have repeatedly shown that four-drug combination regimens offer no greater efficacy than standard three-drug regimens and may be associated with higher rates of adverse events. The selection of ART for the treatment-naive patient is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33682/abstract/1\">",
"      Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33682/abstract/2\">",
"      INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33682/abstract/3\">",
"      Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33682/abstract/4\">",
"      Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008; 197:1006.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3794 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33682=[""].join("\n");
var outline_f32_57_33682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ABBREVIATIONS USED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NELFINAVIR PLUS EFAVIRENZ PLUS NRTIS (ACTG 384)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFAVIRENZ VERSUS NELFINAVIR VERSUS BOTH (INITIO)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ZIDOVUDINE/LAMIVUDINE/ABACAVIR/EFAVIRENZ (ACTG 5095)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33683="Alopecia in secondary syphilis";
var content_f32_57_33683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patchy alopecia in secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair loss associated with secondary syphilis is usually patchy, producing a so-called moth-eaten appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33683=[""].join("\n");
var outline_f32_57_33683=null;
var title_f32_57_33684="Poliovirus vaccine (inactivated): Pediatric drug information";
var content_f32_57_33684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Poliovirus vaccine (inactivated): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/58/35749?source=see_link\">",
"    see \"Poliovirus vaccine (inactivated): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11537?source=see_link\">",
"    see \"Poliovirus vaccine (inactivated): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      IPOL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Polio",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated Bacteria",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/58/35749?source=see_link\">",
"      see \"Poliovirus vaccine (inactivated): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., SubQ: 0.5 mL per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: Recommended schedule: A total of 4 doses administered at 2 months, 4 months, between 6-18 months, and between 4-6 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Catch-up schedule:",
"     <b>",
"      Note:",
"     </b>",
"     Age at initiation of vaccination series:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4 months-17 years: A total of 3 injections 4 weeks apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults: Not routinely recommended unless at increased risk of exposure; a total of 3 doses with second and third doses administered 1-2 months and 6-12 months later; if sufficient time is not available, alternative schedules with three doses given 1 month apart, or two doses given 1 month apart, or a single dose have been used depending upon the expediency desired",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     IPOL&reg;: Type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL, 5 mL) [contains 2-phenoxyethanol, formaldehyde, calf serum protein, neomycin (may have trace amounts), streptomycin (may have trace amounts), and polymyxin B (may have trace amounts)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.M. or SubQ into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults;",
"     <b>",
"      not for I.V. administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate; do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunity to poliovirus (FDA approved in ages &ge;6 weeks and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12705163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Poliovirus vaccine (inactivated) may be confused with tuberculin products. Medication errors have occurred when poliovirus vaccine (IPV) has been inadvertently administered instead of tuberculin skin tests (PPD). These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Fever (&gt;39&deg;C), irritability (most common in infants 2 months of age), tiredness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Swelling, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Persistent crying",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactic shock, anaphylaxis, febrile seizures, hypersensitivity reactions, lymphadenopathy, seizures; Guillain-Barr&eacute; syndrome has been temporally related to another inactivated poliovirus vaccine",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component including neomycin, streptomycin, or polymyxin B; defer vaccination for persons with acute febrile illness until recovery",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9606986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use. Although there is no convincing evidence documenting adverse effects of polio vaccine to the pregnant woman or developing fetus, it is prudent on theoretical grounds to avoid vaccinating pregnant women unless the woman is at increased risk of infection and requires immediate protection. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2983218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted. Although adverse effects of IPV have not been documented in pregnant women or their fetuses, vaccination of pregnant women should be avoided on theoretical grounds. Pregnant women at increased risk for infection and requiring immediate protection against polio may be administered the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1061209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     DTP, MMR, HIB, and hepatitis B vaccines may be given concurrently if at different sites; oral polio vaccine (OPV) is no longer distributed in the United States; OPV is the vaccine of choice for global eradication in areas with continued or recent circulation of wild-type poliovirus, most developing countries where the higher cost of IPV prohibits its use or where inadequate sanitation necessitates an optimal barrier to wild-type virus circulation (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2006)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Recommended Immunization Schedules for Persons Aged 0 Through 18 Years &minus; United States, 2009,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 57(51-52):Q1-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prevots DR, Burr RK, and Sutter RW, &ldquo;Poliomyelitis Prevention in the United States: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-5):1-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/ 15580728 /pubmed\" id=\" 15580728 \" target=\"_blank\">",
"        15580728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33684/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2006 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 27th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2006, 545.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12967 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33684=[""].join("\n");
var outline_f32_57_33684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061202\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061195\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211013\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211001\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061206\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061199\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061205\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705163\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211037\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061208\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606986\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061194\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299896\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211008\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211010\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983218\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929247\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061209\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12967|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/58/35749?source=related_link\">",
"      Poliovirus vaccine (inactivated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11537?source=related_link\">",
"      Poliovirus vaccine (inactivated): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33685="Idarubicin: Pediatric drug information";
var content_f32_57_33685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Idarubicin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"    see \"Idarubicin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/40/29317?source=see_link\">",
"    see \"Idarubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Idamycin PFS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Idamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Anthracycline",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"      see \"Idarubicin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AML: I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 10-12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 3 days of treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction: 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Consolidation: 10-12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic and/or renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine &ge;2 mg/dL: Reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;2.5 mg/dL: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;5 mg/dL:",
"     <b>",
"      Do not administer",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 1 mg/mL (5 mL, 10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Idamycin PFS&reg;: 1 mg/mL (5 mL, 10 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Do not administer I.M. or SubQ",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Administer by I.V. intermittent infusion over 10-30 minutes into a free flowing I.V. solution of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W; administer at a final concentration of 1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F181734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, sterile water for injection,",
"     <b>",
"      incompatible",
"     </b>",
"     with bacteriostatic water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amikacin, aztreonam, cimetidine, cladribine, cyclophosphamide, cytarabine, diphenhydramine, droperidol, erythromycin lactobionate, etoposide phosphate, filgrastim, gemcitabine, granisetron, magnesium sulfate, mannitol, melphalan, metoclopramide, potassium chloride, ranitidine, sargramostim, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, allopurinol, ampicillin/sulbactam, cefazolin, cefepime, ceftazidime, clindamycin, dexamethasone sodium phosphate, etoposide, fluorouracil, furosemide, gentamicin, heparin, hydrocortisone sodium succinate, lorazepam, meperidine, methotrexate, piperacillin/tazobactam, sodium bicarbonate, teniposide, vancomycin, vincristine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Imipenem/cilastatin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vials under refrigeration and protect from light; incompatible with acyclovir, ceftazidime, furosemide, hydrocortisone, sodium bicarbonate and heparin; inactivated by alkaline solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used in combination with other antineoplastic agents for treatment of acute myeloid leukemia (AML) (FDA approved in adults); has also been used for the treatment of acute lymphocytic leukemia (ALL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       IDArubicin may be confused with DOXOrubicin, DAUNOrubicin, epirubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Idamycin PFS&reg; may be confused with Adriamycin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: CHF (dose related), transient ECG abnormalities (supraventricular tachycardia, S-T wave changes, atrial or ventricular extrasystoles) are generally asymptomatic and self-limiting. The relative cardiotoxicity of idarubicin compared to doxorubicin is unclear. Some investigators report no increase in cardiac toxicity for adults at cumulative oral idarubicin doses up to 540 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; other reports suggest a maximum cumulative intravenous dose of 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, radiation recall, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, GI hemorrhage, nausea, vomiting, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emetic potential: Moderate (30% to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine (darker yellow)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (nadir: 10-15 days; recovery: 21-28 days), primarily leukopenia; thrombocytopenia and anemia. Effects are generally less severe with oral dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Tissue necrosis upon extravasation, erythematous streaking",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Cardiomyopathy, hyperuricemia, myocarditis, neutropenic typhlitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to idarubicin or any component; patients with pre-existing bone marrow suppression unless the benefit warrants the risk; severe CHF, cardiomyopathy, or arrhythmias; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dose in patients with impaired hepatic or renal function",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     and patients receiving concurrent radiation therapy. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; I.V. use only, severe local tissue necrosis will result if extravasation occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . May cause myocardial toxicity (CHF, arrhythmias or cardiomyopathies)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; myocardial toxicity is more common in patients who have previously received anthracyclines or have pre-existing cardiac disease; the risk of myocardial toxicity is also increased in patients with concomitant or prior mediastinal/pericardial irradiation, patients with anemia, bone marrow depression, infections, leukemic pericarditis, or myocarditis. Monitor cardiac function during treatment; the maximum lifetime anthracycline dose for idarubicin is approximately 137.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; may cause severe myelosuppression",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; myelosuppression occurs in all patients given a therapeutic dose and is the dose-limiting adverse effect associated with idarubicin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies. Fetal fatality was noted in a case report following use in a pregnant woman during the second trimester. The manufacturer recommends that women of childbearing potential avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, ECHO, ECG, serum electrolytes, creatinine, uric acid, ALT, AST, bilirubin, signs of extravasation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intercalates with DNA causing strand breakage and affects topoisomerase II activity resulting in inhibition of chain elongation and inhibition of DNA and RNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Large volume of distribution due to extensive tissue binding; distributes into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : 1700 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Idarubicin: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Idarubicinol: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to idarubicinol (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 18.7 hours (range: 2.5-22.4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 19 hours (range: 10.5-34.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Idarubicinol: 45-56.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily by biliary excretion; 2.3% to 6.5% of a dose is eliminated renally",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/40/29317?source=see_link\">",
"      see \"Idarubicin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, bleeding, bruising, or pain at infusion site occurs. Urine may turn pink or red. Contraceptive measures are recommended during therapy.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dinndorf PA, Avramis VI, Wiersma S, et al, &ldquo;Phase I/II Study of Idarubicin Given With Continuous Infusion Fludarabine Followed by Continuous Infusion Cytarabine in Children With Acute Leukemia: A Report From the Children's Cancer Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(8):2780-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33685/abstract-text/9256119/pubmed\" id=\"9256119\" target=\"_blank\">",
"        9256119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leahey A, Kelly K, Rorke LB, et al, &ldquo;A Phase I/II Study of Idarubicin (Ida) With Continuous Infusion Fludarabine (F-ara-A) and Cytarabine (ara-C) for Refractory or Recurrent Pediatric Acute Myeloid Leukemia (AML),&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 1997, 19(4):304-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33685/abstract-text/ 9256828 /pubmed\" id=\" 9256828 \" target=\"_blank\">",
"        9256828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reid JM, Pendergrass TW, Krailo MD, et al, &ldquo;Plasma Pharmacokinetics and Cerebrospinal Fluid Concentrations of Idarubicin and Idarubicinol in Pediatric Leukemia Patients: A Children's Cancer Study Group Report,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1990, 50(20):6525-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/57/33685/abstract-text/2208112/pubmed\" id=\"2208112\" target=\"_blank\">",
"        2208112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13372 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33685=[""].join("\n");
var outline_f32_57_33685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708916\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181682\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181683\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047789\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047782\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181660\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181645\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047793\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181734\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047784\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047792\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181737\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181733\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047796\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047781\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047780\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838176\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181654\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181656\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206274\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047788\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047779\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047795\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047786\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13372|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=related_link\">",
"      Idarubicin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/40/29317?source=related_link\">",
"      Idarubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33686="Countercurrent mechanism Review";
var content_f32_57_33686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Countercurrent mechanism - Review",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 496px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of the steps involved in countercurrent multiplication in which a concentration gradient is established that permits passive NaCl reabsorption in the thin ascending limb in the inner medulla. The thickened lines represent the water impermeability of the ascending limb. See text for details.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33686=[""].join("\n");
var outline_f32_57_33686=null;
var title_f32_57_33687="Nikolsky sign";
var content_f32_57_33687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Nikolsky sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A and B show the Nikolsky sign elicited by rubbing the skin at the periphery of an existing lesion. Panels C and D show the Nikolsky sign elicited by rubbing the normal-appearing skin distant from the lesions. These two methods appear to have different sensitivity and specificity for pemphigus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uzun S, Durdu M. The specificity and sensitivity of Nikolsky sign in the diagnosis of pemphigus. J Am Acad Dermatol 2006; 54:411. Copyright &copy; 2006 The American Academy of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33687=[""].join("\n");
var outline_f32_57_33687=null;
var title_f32_57_33688="Role of surgery in the management of peptic ulcer disease";
var content_f32_57_33688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of surgery in the management of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Ashley H Vernon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33688/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/57/33688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease only infrequently requires operation, although it was once the most common indication for gastric surgery. Over the last two decades, the development of potent antisecretory agents (H2 blockers and proton pump inhibitors) and the recognition that treatment for Helicobacter pylori infection can eliminate most ulcer recurrences have essentially obviated the need for surgery in the elective treatment of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, surgery is still required in several unusual settings and it remains a mainstay in the emergency therapy of life-threatening complications of aggressive and advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, an understanding of the surgical procedures is important since there remain a significant number of patients who required operation before the development of these new therapies. Some of these patients continue to suffer from the negative consequences of these procedures, the so-called postgastrectomy syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative therapy for peptic ulcer has traditionally been indicated for bleeding, perforation, obstruction, and intractability. The definition of when an ulcer should be considered intractable remains uncertain, and this indication is increasingly unusual. No algorithm can replace experienced judgment that is tailored for the individual patient.",
"   </p>",
"   <p>",
"    Contemporary indications for ulcer surgery include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of nonoperative management of an ulcer complication. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link\">",
"       \"Overview of the complications of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suspicion of malignancy, usually in a gastric ulcer. Even if biopsies are benign, a gastric ulcer that has failed to heal after 12 weeks of medical therapy is usually considered an indication for operation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More controversial and infrequent indications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient preference, although today this is distinctly unusual.",
"     </li>",
"     <li>",
"      Intolerance or noncompliance with a medical regimen.",
"     </li>",
"     <li>",
"      Patients who are at high risk for ulcer complications, such as transplant recipients, and those who are steroid- or NSAID-dependent.",
"     </li>",
"     <li>",
"      Patients with a giant gastric or duodenal ulcer (although most of these can be healed with medical therapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A strong ulcer diathesis as evidenced by severe symptoms, failure to heal on medical therapy (including antimicrobials), and relapse while on maintenance therapy or after multiple courses of therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=see_link\">",
"       \"Refractory or recurrent peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elective operation for peptic ulcer is rare in current practice. However, excessive reliance on pharmacotherapy, reluctance to admit failure of medical or endoscopic management, and an exaggerated fear of the consequences of surgical intervention may delay an appropriate operation. Such a delay could convert a potentially elective or semi-elective situation to an emergency one, with an attendant increase in perioperative morbidity and mortality.",
"   </p>",
"   <p>",
"    The fundamental goals of surgical therapy are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Permit ulcer healing",
"     </li>",
"     <li>",
"      Prevent or treat ulcer complications",
"     </li>",
"     <li>",
"      Address the underlying ulcer diathesis",
"     </li>",
"     <li>",
"      Minimize postoperative digestive sequelae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No single procedure satisfies all of the stated goals, nor is any specific operation applicable in all clinical settings. In some respects, all ulcer operations represent a compromise: the morbidity of ulcer disease is replaced by the morbidity of the operation. To optimize therapy, the surgeon must consider:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Characteristics of the ulcer (location, chronicity, presence of complications)",
"     </li>",
"     <li>",
"      The patient (age, nutrition, comorbid illness, condition on presentation)",
"     </li>",
"     <li>",
"      The operation (mortality rate, side effects).",
"     </li>",
"     <li>",
"      Their experience; today most surgical residents complete their training with significantly less experience with the more complex procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/4\">",
"       4",
"      </a>",
"      ], which undoubtedly influences their choices for both elective and emergent operations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different elective surgical techniques used in the treatment of duodenal and gastric ulcers and their consequences will be reviewed here. The management of patients with complications of ulcer disease (perforation, gastric outlet obstruction, and bleeding) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OPERATION FOR DUODENAL ULCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although medical therapy for duodenal ulcer has shifted away from",
"    <span class=\"nowrap\">",
"     antisecretory/antacid",
"    </span>",
"    approaches in favor of an antimicrobial strategy, operative therapy continues to be based upon the reduction of acid secretion. Acid secretion by the parietal cells is normally stimulated by acetylcholine from the vagus nerve and gastrin release from the antrum. Thus, surgical approaches attempt to reduce this secretion by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sectioning the vagus (vagotomy)",
"     </li>",
"     <li>",
"      Eliminating hormonal stimulation from the antrum (antrectomy)",
"     </li>",
"     <li>",
"      Decreasing the number of parietal cells (gastric resection).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these maneuvers has effects on acid secretion and consequences in terms of the normal physiology of the upper gastrointestinal tract, which tend to be amplified when the procedures are combined (eg, vagotomy and antrectomy).",
"   </p>",
"   <p>",
"    In the past, the choice of operation involved weighing the rates of recurrent ulceration with the risk of postoperative complications and long-term sequelae, referred to as the postgastrectomy syndromes. This decision prompted a large number of trials comparing the procedures in the surgical literature. More recently, improvements in medical therapy, particularly treatment of H. pylori, have markedly reduced the risk of recurrence, rendering much of these data obsolete. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vagotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for vagotomy is the elimination of direct cholinergic stimulation to acid secretion. This also makes the parietal cells less responsive to histamine and gastrin and abolishes the vagal stimulus for release of antral gastrin.",
"   </p>",
"   <p>",
"    Three different types of vagotomy are performed: truncal, selective, and highly selective (also referred to as parietal cell or proximal gastric vagotomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Truncal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Truncal vagotomy is the simplest procedure; the anterior and posterior vagus nerves are identified on the distal esophagus, and a small section is removed and sent for histology to confirm that the nerve has been identified and sectioned. Basal and stimulated acid secretions are reduced by 80 and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this alone significantly reduces acid secretion, it also markedly alters gastric motility, impairing both the receptive relaxation of the stomach and the process of antral grinding and pyloric sphincter coordination, trituration, which permits gastric emptying. Gastric emptying of liquids is speeded with the loss of relaxation, whereas solid evacuation is slowed significantly, leading to gastric stasis in some patients.",
"   </p>",
"   <p>",
"    As a result, some form of gastric emptying procedure (pyloroplasty or gastroenterostomy) must be performed (",
"    <a class=\"graphic graphic_figure graphicRef63194 \" href=\"mobipreview.htm?28/32/29185\">",
"     figure 1",
"    </a>",
"    ). At least three different types of pyloroplasty (Heinecke-Mikulicz, Finney, Jaboulay), dividing or bypassing the pyloric sphincter mechanism, have been described. The Heineke Mikulicz pyloroplasty, which divides the sphincter longitudinally and closes it transversely, is the simplest technically and is most commonly performed. Gastroenterostomy, an anastomosis between the dependent stomach and proximal jejunum, is typically reserved for patients with significant duodenal bulb scarring, which would make pyloroplasty more difficult. Although it has never been demonstrated to be clinically superior, pyloroplasty preserves the normal anatomic relationship between the stomach and duodenum and is generally preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Selective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Truncal vagotomy sacrifices innervation to the pancreas, small intestine, proximal colon, and hepatobiliary tree. By contrast, selective vagotomy spares the hepatic and celiac divisions of the vagal trunks. The technique was introduced with the hope that limiting vagotomy to the stomach would result in milder postoperative metabolic and digestive sequelae. A drainage procedure is still required since the antrum is denervated. Prospective studies have failed to show substantial benefit over truncal vagotomy, and selective vagotomy has fallen out of favor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Highly selective",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for highly selective vagotomy is to eliminate the vagal stimulation to the acid-secreting portion of the stomach without interrupting motor innervation to the antrum and pylorus. The operation involves severing all branches of the vagus nerves along the lesser curvature that innervate the corpus and fundus of the stomach. Basal and stimulated acid secretions are reduced by more than 75 percent and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/5\">",
"     5",
"    </a>",
"    ]. This procedure minimizes the effects of vagotomy on gastric emptying. Although receptive relaxation is still impaired, and emptying of liquids is more rapid than normal, antral peristalsis and sphincter function are preserved so that solid emptying is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastric resection procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtotal gastrectomy is most commonly used for gastric ulcer and distal gastric malignancies. In the past, it was also used for treatment of duodenal ulcer disease. The distal two-thirds of the stomach, including the pylorus, are removed. This eliminates not only a major portion of the parietal cells, but also the antrum, removing the gastrin stimulus to acid secretion. This operation reduces basal and stimulated acid secretion by 75 percent and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/5\">",
"     5",
"    </a>",
"    ]. The emptying of both liquids and solids is more rapid and, with removal of the pylorus, increased reflux of intestinal contents into the stomach may produce significant reflux gastritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Truncal vagotomy with antrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Truncal vagotomy with antrectomy was, until recently, among the most commonly performed procedures for duodenal ulcer disease. The simultaneous effects of vagotomy and antrectomy remove both the cholinergic and gastrin stimulus to acid secretion. Basal acid secretion is virtually abolished and stimulated secretion is reduced by nearly 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After partial gastrectomy, gastrointestinal continuity must be restored by some form of reconstruction (",
"    <a class=\"graphic graphic_figure graphicRef60974 \" href=\"mobipreview.htm?15/7/15475\">",
"     figure 2",
"    </a>",
"    ). The remnant is anastomosed either to the duodenum (Billroth I) or, after closing the duodenal stump, to the jejunum distal to the ligament of Treitz (Billroth II). The Billroth I procedure has theoretical physiologic advantages because it is a more anatomical approach. The Billroth II has both an afferent limb from the duodenum and an efferent limb extending distally.",
"   </p>",
"   <p>",
"    For a Billroth II reconstruction, the jejunal anastomosis may be performed in an antecolic or retrocolic, isoperistaltic or antiperistaltic fashion (",
"    <a class=\"graphic graphic_figure graphicRef80302 \" href=\"mobipreview.htm?13/35/13876\">",
"     figure 3",
"    </a>",
"    ). Functional differences between these have not been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the antecolic approach appears to lead to fewer internal hernias than the retrocolic approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically, the choice of procedure is based upon the degree of scarring of the duodenum and the ease with which the duodenum and gastric remnant can be brought together. Roux-en-Y reconstruction is occasionally performed to divert the bile away from the remnant, although this requires an additional anastomosis.",
"   </p>",
"   <p>",
"    Although there have been concerns about gastric atony after a Roux-en-Y reconstruction, a prospective randomized study of 75 patients with duodenal ulcers treated from 1984 to 1993 and followed for up to 21 years after surgery demonstrated significantly better clinical outcomes in 36 patients who underwent Roux-en-Y procedures (R-Y) as compared to 39 patients who underwent Billroth II (B-2) procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of reflux esophagitis symptoms for R-Y and B-2 were 3 and 33 percent, respectively. Endoscopic evaluation of the distal esophagus and esophago-gastric junction was normal in 90 percent of the R-Y patients but only 17 percent of the B-2 patients. Barrett's esophagus developed in 3 percent of R-Y patients versus 21 percent of B-2 patients. The gastric remnant was normal in all of R-Y patients compared with 18 percent of the B-2 patients. There was no difference between the groups in the incidence of Helicobacter pylori infection. These finding suggest that R-Y is better tolerated clinically and leads to a lower incidence of Barrett's esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSTGASTRECTOMY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operations on the stomach can lead to a variety of undesirable, chronic sequelae. Although some of these conditions are related more to vagotomy than to resection, they have been referred to collectively as the postgastrectomy syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Virtually all patients note a change in their digestive habits postoperatively, and about 20 percent are significantly affected. Most are able adapt with time; only 5 percent develop lifelong symptoms and 1 percent are significantly debilitated by these syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Postvagotomy diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postvagotomy diarrhea develops in approximately 30 percent of patients after truncal vagotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/11\">",
"     11",
"    </a>",
"    ]. The pathogenesis is unclear, but it may be related to the rapid passage of unconjugated bile salts from the denervated biliary tree into the colon, where they stimulate secretion. Most cases are self limiting; oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , which binds bile salts, can be effective in persistent cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dumping syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dumping occurs in about 20 percent of patients after gastrectomy or vagotomy and drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/11\">",
"     11",
"    </a>",
"    ]. Affected patients have postprandial gastrointestinal discomfort, which may include nausea, vomiting, diarrhea, and cramps, with vasomotor symptoms such as diaphoresis, palpitations, and flushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the precise mechanism is incompletely understood, the syndrome is frequently attributed to the rapid emptying of hyperosmolar chyme (particularly carbohydrates) into the small bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/14\">",
"     14",
"    </a>",
"    ]. This leads to net fluid retention due to the osmotic gradient and probably releases one or more vasoactive hormones, such as serotonin and vasoactive intestinal polypeptide.",
"   </p>",
"   <p>",
"    Less often, patients complain of the same constellation of symptoms hours after eating, so-called late dumping. This phenomenon is thought to be secondary to hypoglycemia from a postprandial insulin peak.",
"   </p>",
"   <p>",
"    Most patients with dumping can be treated conservatively with dietary changes (frequent small meals that are high in protein and fat and low in carbohydrates for early dumping; increased carbohydrate consumption for late dumping) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The rare patient with intractable symptoms may be considered for operative therapy with the goal of delaying gastric emptying (as with the conversion of a vagotomy and pyloroplasty to an antrectomy with Roux-en-Y reconstruction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Symptoms tend to resolve in most patients as they learn to avoid foods that aggravate the problem.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    or an analogue may also help in severe cases of dumping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/14\">",
"     14",
"    </a>",
"    ]. A study of 30 patients with dumping treated with either subcutaneous octreotide, administered three times a day, or long-acting repeatable octreotide formulation, which is given monthly, reported that both formulations significantly reduced dumping symptoms and improved quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients preferred monthly treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alkaline reflux gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflux of bile into the stomach is common after operations that eliminate the pyloric sphincter. In most patients there are no serious clinical sequelae. However, approximately 2 percent of patients develop alkaline reflux gastritis, a syndrome of persistent burning epigastric pain and chronic nausea that is aggravated by meals. The diagnosis is made primarily by excluding other causes of symptoms, although endoscopy may reveal gastritis, and technetium biliary scan can demonstrate increased reflux of bile into the stomach. A variety of medical therapies has been reported but none have proven particularly effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9384?source=see_link\">",
"     \"Acute hemorrhagic erosive gastropathy and chronic chemical gastropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Early satiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early satiety may develop as a result of postsurgical atony, gastric stasis as a result of denervation, or from the \"small gastric remnant syndrome\" related to resection. Symptoms consist of epigastric fullness with meals, often followed by emesis.",
"   </p>",
"   <p>",
"    Atony can be identified with a solid food emptying test and may respond to prokinetic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . If these fail, completion gastrectomy may be required, although there is some anecdotal evidence that gastric pacing may prove useful.",
"   </p>",
"   <p>",
"    The \"small gastric remnant syndrome\" will usually improve with small frequent feedings and time. Vitamin B12 injections may be required and deficiencies of iron and calcium can require supplementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Afferent and efferent loop syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Afferent and efferent loop syndromes develop after Billroth II reconstruction or gastroenterostomy. They are related to mechanical obstruction of the limbs by kinking, anastomotic narrowing, or adhesions. Afferent loop syndrome is typically associated with postprandial epigastric pain and nonbilious vomiting that is then relieved by projectile bilious vomiting. The detection of distended afferent loop on CT is diagnostic. Conversion to a Roux-en-Y anastomosis is necessary to treat this problem. Efferent loop syndrome is associated with epigastric pain, distension, and bilious vomiting; operation is the treatment of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Choice of operation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliable data on the results of the various operations for duodenal ulcer (mainly vagotomy and antrectomy, vagotomy and drainage, and highly-selective vagotomy) were generated by a series of trials during the last half of the twentieth century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/16-29\">",
"     16-29",
"    </a>",
"    ]. Comparison of these reports is limited by their heterogeneity since they used different criteria for patient selection and for estimating the incidence of side effects. The following are reasonable general observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality and early morbidity were highest for vagotomy and drainage and lowest for highly selective vagotomy, which avoids opening the gastrointestinal tract.",
"     </li>",
"     <li>",
"      The relative incidence of side effects was about the same for vagotomy and antrectomy or drainage, and significantly lower for highly selective vagotomy.",
"     </li>",
"     <li>",
"      Recurrence rates were significantly lower for vagotomy and antrectomy.",
"     </li>",
"     <li>",
"      Truncal vagotomy with drainage had both the higher recurrence rate of highly selective vagotomy and the unfavorable side effects of vagotomy and antrectomy.",
"     </li>",
"     <li>",
"      Most surgeons favored highly selective vagotomy for its low incidence of side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these data are probably no longer applicable. With treatment of H. pylori, it is believed that recurrences have been mostly eliminated, although no data in this setting have yet been generated. Although this would more strongly favor highly selective vagotomy, today experience with this more complex procedure is so unusual that it is seldom chosen. In addition, most patients undergoing operation now are elderly and debilitated, conditions favoring the most expeditious procedure, usually truncal vagotomy and drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laparoscopic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing number of reports of laparoscopic approaches to operations for duodenal ulcer have appeared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. All procedures have been described laparoscopically, including the more difficult selective vagotomy, although the Taylor procedure, anterior seromyotomy with posterior truncal vagotomy, seems to be the simplest option particularly when the serosal myotomy is performed as a stapled anterior linear gastrotomy. Several reports have suggested that side-effects of the Taylor procedure are similar to highly selective vagotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These series demonstrate clearly that laparoscopic ulcer surgery is feasible, probably safe, and possibly effective. However, enthusiasm for minimally invasive approaches should be tempered with skepticism while the collective experience remains limited. Unfortunately, given the infrequency of these operations today, it seems unlikely that extensive experience will be generated in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gastric cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone gastric resection for benign gastric or duodenal ulcer disease may be at increased risk for development of gastric cancer. The risk in various series has ranged from 0.8 to as high as 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/37-45\">",
"     37-45",
"    </a>",
"    ], although an increased risk has not been uniformly reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Among studies that showed an increased risk, the risk appeared to increase 15 to 20 years after the initial surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/38,40-42,45,48\">",
"     38,40-42,45,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A benefit from endoscopic surveillance of postgastrectomy patients has not been established. Guidelines issued by the American Society for Gastrointestinal Endoscopy suggest the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are insufficient data to support routine endoscopic surveillance for patients with previous partial gastrectomy for peptic ulcer disease.",
"     </li>",
"     <li>",
"      Before gastric surgeries are performed for peptic ulcer disease, an index endoscopy should be performed to establish the presence of H. pylori infection, chronic gastritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intestinal metaplasia.",
"     </li>",
"     <li>",
"      If endoscopic surveillance is considered, it should be initiated after an interval of 15 to 20 years. Multiple biopsies from the anastomosis and gastric remnant should be taken. The threshold should be low to evaluate upper gastrointestinal symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OPERATION FOR GASTRIC ULCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both gastric and duodenal ulcers are peptic lesions, fundamental differences between these entities affect surgical strategy. The most important is that gastric ulcer may harbor malignancy and therefore must be excised or generously biopsied. In addition, gastric ulcer tends to affect an older and more debilitated population, increasing the potential for perioperative morbidity and mortality.",
"   </p>",
"   <p>",
"    A classification system (the Johnson classification) based upon anatomic location and acid-secretory potential provides a useful basis for considering operative treatment of gastric ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Type I gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I ulcers are the most common form. These occur along the lesser curvature at the junction of fundic and antral mucosa, and occur in the setting of acid hyposecretion. Distal gastrectomy with Billroth I or II reconstruction is recommended for most patients, since this approach removes the ulcer and the diseased antrum. It also eliminates the risk of missing a malignancy associated with biopsy. Acid secretory potential is reduced and gastric drainage is accelerated. Low recurrence rates (0 to 5 percent) and excellent symptomatic relief are usually achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/51\">",
"     51",
"    </a>",
"    ]. Mortality rates range from 0 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although type I gastric ulcer has classically been considered the consequence of inadequate mucosal defense, rather than increased acid secretion, many advocate the addition of some form of vagotomy to the gastric resection. This issue was most recently addressed in a review of the Cleveland Clinic experience with 349 cases of gastric ulcer from 1950 to 1979 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/53\">",
"     53",
"    </a>",
"    ]. Median follow-up was more than 11 years. Equivalent recurrence rates were noted for gastric resection with or without vagotomy. This study also found comparable results for truncal vagotomy and pyloroplasty plus ulcer excision or biopsy. Thus, vagotomy is unnecessary but not unreasonable for type I gastric ulcer.",
"   </p>",
"   <p>",
"    Although most prefer distal gastrectomy, highly selective vagotomy has been used for type I gastric ulcer. The procedure is performed as for duodenal ulcer with the addition of a gastrotomy to excise or biopsy the ulcer bed. This approach has been questioned on theoretical grounds because highly selective vagotomy may promote a degree of gastric stasis and gastrin hypersecretion, two factors hypothesized to contribute to gastric ulcerogenesis. Despite these concerns, clinical results have been promising. In one series of 48 patients, for example, the recurrent rate was 6.5 percent with few side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of highly selective vagotomy in gastric ulcer may derive from its ability to decrease acid secretion while maintaining adequate gastric emptying and minimizing postoperative duodenogastric reflux. Ulcer size and location may make this operative approach untenable for some patients in whom ulcer-induced inflammation, edema, or scarring may obscure accurate dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Type II gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II gastric ulcers occur synchronously with scarring or ulceration in the duodenum or pyloric channel. They tend to be large, deep ulcers, with poorly defined margins. They frequently occur in younger men and are associated with increased acid secretion. Treatment is similar to duodenal ulcer, with vagotomy and antrectomy the preferred approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Type III gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type III ulcers are prepyloric, although no precise anatomic definition exists. They occur in the setting of increased acid secretion aggression and are approached in a manner similar to duodenal ulcer and type II gastric ulcer. Curiously, highly selective vagotomy (as well as medical therapy with H2 receptor antagonists) has been associated with poor results in type III gastric ulcer, with recurrence rates ranging from 16 to 44 percent in various series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33688/abstract/53\">",
"     53",
"    </a>",
"    ]. This finding plus the observation that these lesions may harbor gastric malignancy makes vagotomy and antrectomy the most prudent approach. Early consideration of surgical referral is advisable for resistant ulcers or those that present with obstructive symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Type IV gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IV gastric ulcer is distinguished by its anatomic location high along the lesser curvature, close to the gastroesophageal junction. Antral mucosa may extend to within 1 to 2 cm of the gastroesophageal junction; thus, type IV ulcers may simply represent a subset of type I gastric ulcer.",
"   </p>",
"   <p>",
"    Type IV ulcers are associated with gastric hyposecretion and present early with dysphagia and reflux. Large ulcer size, the degree of surrounding inflammation, and proximity to the gastroesophageal junction render operative management difficult and potentially dangerous. If the integrity of the distal esophagus can be assured, subtotal gastric resection (including the ulcer bed) is considered optimal. Alternatives include a distal gastrectomy which is extended along the lesser curvature to include the ulcer, the Pauchet procedure, or the Kelly-Madlener procedure in which distal gastrectomy is performed but the ulcer is left in place to avoid compromise of the gastroesophageal junction.",
"   </p>",
"   <p>",
"    Although there is no consensus in the literature, many surgeons feel more comfortable performing an esophageal anastomosis knowing that the ulcer is removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative management of peptic ulcer disease (PUD) is reserved for ulcers refractory to medical management. The development of potent antisecretory agents (H2 blockers and proton pump inhibitors) and the recognition that treatment for Helicobacter pylori infection can eliminate most ulcer recurrences have essentially obviated the need for surgery in the elective treatment of this disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for operative management of PUD include: failure of nonoperative management and suspicion of a malignancy in an ulcer that failed to heal after 12 weeks of medical therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infrequent indications for operative management of PUD include: patient preference, noncompliance with medical management, patients at high risk of ulcerative complications, giant gastric or duodenal ulcers, refractory or recurrent disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Goals of operative management of PUD include: prevent or treat ulcer complications, address underlying ulcer diathesis, and minimize digestive sequelae of the procedure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The operative therapy for duodenal ulcers is based upon the reduction of acid secretion by performing a truncal vagotomy, a selective vagotomy or a highly selective vagotomy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Operation for duodenal ulcer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Truncal vagotomy and antrectomy is the gold standard operative procedure for duodenal ulcers, as it removes both the cholinergic and gastrin stimulus to acid secretion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Operation for duodenal ulcer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Digestive changes related to a gastrectomy procedure are noted by almost all patients; however, only 20 percent have serious complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Postgastrectomy syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/1\">",
"      Kauffman GL Jr. Duodenal ulcer disease: treatment by surgery, antibiotics, or both. Adv Surg 2000; 34:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/2\">",
"      Lickstein, LH, Matthews, JB. Elective surgical management of peptic ulcer disease. Probl General Surgery 1997; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/3\">",
"      Simeone DM, Hassan A, Scheiman JM. Giant peptic ulcer: a surgical or medical disease? Surgery 1999; 126:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/4\">",
"      Espat NJ, Ong ES, Helton WS, Nyhus LM. 1990-2001 US general surgery chief resident gastric surgery operative experience: analysis of paradigm shift. J Gastrointest Surg 2004; 8:471.",
"     </a>",
"    </li>",
"    <li>",
"     Ashley SW, Evoy D, Daly JM. Stomach. In; Principles of Surgery. Seventh Edition. Schwartz SS (Ed), McGraw-Hill, New York, 1999, p. 1181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/6\">",
"      Hoffmann J, Jensen HE, Christiansen J, et al. Prospective controlled vagotomy trial for duodenal ulcer. Results after 11-15 years. Ann Surg 1989; 209:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/7\">",
"      Amdrup E, Andersen D, H&oslash;strup H. The Aarhus County vagotomy trial. I. An interim report on primary results and incidence of sequelae following parietal cell vagotomy and selective gastric vagotomy in 748 patients. World J Surg 1978; 2:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/8\">",
"      Houghton AD, Liepins P, Clarke S, Mason R. Iso- or antiperistaltic anastomosis: does it matter? J R Coll Surg Edinb 1996; 41:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/9\">",
"      Steele KE, Prokopowicz GP, Magnuson T, et al. Laparoscopic antecolic Roux-en-Y gastric bypass with closure of internal defects leads to fewer internal hernias than the retrocolic approach. Surg Endosc 2008; 22:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/10\">",
"      Csendes A, Burgos AM, Smok G, et al. Latest results (12-21 years) of a prospective randomized study comparing Billroth II and Roux-en-Y anastomosis after a partial gastrectomy plus vagotomy in patients with duodenal ulcers. Ann Surg 2009; 249:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/11\">",
"      Glasgow, RE, Mulvihill, SJ. Postgastrectomy syndromes. Probl General Surgery 1997; 14:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/12\">",
"      Eagon JC, Miedema BW, Kelly KA. Postgastrectomy syndromes. Surg Clin North Am 1992; 72:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/13\">",
"      Miedema BW, Kelly KA. The Roux operation for postgastrectomy syndromes. Am J Surg 1991; 161:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/14\">",
"      Vecht J, Gielkens HA, Fr&ouml;lich M, et al. Vasoactive substances in early dumping syndrome: effects of dumping provocation with and without octreotide. Eur J Clin Invest 1997; 27:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/15\">",
"      Arts J, Caenepeel P, Bisschops R, et al. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. Clin Gastroenterol Hepatol 2009; 7:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/16\">",
"      Humphrey CS, Johnston D, Walker BE, et al. Incidence of dumping after truncal and selective vagotomy with pyloroplasty and highly selective vagotomy without drainage procedure. Br Med J 1972; 3:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/17\">",
"      Price WE, Grizzle JE, Postlethwait RW, et al. Results of operation for duodenal ulcer. Surg Gynecol Obstet 1970; 131:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/18\">",
"      Jordan PH Jr, Condon RE. A prospective evaluation of vagotomy-pyloroplasty and vagotomy-antrectomy for treatment of duodenal ulcer. Ann Surg 1970; 172:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/19\">",
"      Goligher JC, Pulvertaft CN, De Dombal FT, et al. Five to eight-year results of Leeds-York controlled trial of elective surgery for duodenal ulcer. Br Med J 1968; 2:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/20\">",
"      Macintyre IM, Millar A, Smith AN, Small WP. Highly selective vagotomy 5-15 years on. Br J Surg 1990; 77:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/21\">",
"      Herrington, JL, Davidson, J, Shumway, SJ. Proximal gastric vagotomy: Follow-up of 109 patients for 6-13 years. Ann Surg 1986; 204:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/22\">",
"      Hoffmann J, Olesen A, Jensen HE. Prospective 14- to 18-year follow-up study after parietal cell vagotomy. Br J Surg 1987; 74:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/23\">",
"      Sawyers JL, Herrington JL Jr, Burney DP. Proximal gastric vagotomy compared with vagotomy and antrectomy and selective gastric vagotomy and pyloroplasty. Ann Surg 1977; 186:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/24\">",
"      Sta&euml;l von Holstein C, Graffner H, Oscarson J. One hundred patients ten years after parietal cell vagotomy. Br J Surg 1987; 74:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/25\">",
"      Byrne DJ, Brock BM, Morgan AG, McAdam WA. Highly selective vagotomy: a 14-year experience. Br J Surg 1988; 75:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/26\">",
"      Soper NJ, Kelly KA, van Heerden JA, Ilstrup DM. Long term clinical results after proximal gastric vagotomy. Surg Gynecol Obstet 1989; 169:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/27\">",
"      Koruth NM, Dua KS, Brunt PW, Matheson NA. Comparison of highly selective vagotomy with truncal vagotomy and pyloroplasty: results at 8-15 years. Br J Surg 1990; 77:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/28\">",
"      Johnston GW, Spencer EF, Wilkinson AJ, Kennedy TL. Proximal gastric vagotomy: follow-up at 10-20 years. Br J Surg 1991; 78:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/29\">",
"      Jordan PH Jr, Thornby J. Twenty years after parietal cell vagotomy or selective vagotomy antrectomy for treatment of duodenal ulcer. Final report. Ann Surg 1994; 220:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/30\">",
"      Spivak, H, Hunter, JG. Laparoscopic gastric surgery. Probl Gen Surg 1997; 14:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/31\">",
"      Weerts JM, Dallemagne B, Jehaes C, Markiewicz S. Laparoscopic gastric vagotomies. Ann Chir Gynaecol 1994; 83:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/32\">",
"      Cadi&eacute;re GB, Himpens J, Bruyns J. Laparoscopic proximal gastric vagotomy. Endosc Surg Allied Technol 1994; 2:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/33\">",
"      Croce E, Azzola M, Golia M, et al. Laparoscopic posterior truncal vagotomy and anterior proximal gastric vagotomy. Endosc Surg Allied Technol 1994; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/34\">",
"      Katkhouda N, Heimbucher J, Mouiel J. Laparoscopic posterior vagotomy and anterior seromyotomy. Endosc Surg Allied Technol 1994; 2:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/35\">",
"      Gomez-Ferrar, F. Gastrectomie lineaire anterieure et vagotomie tronculaire posteriere una nouvelle technique laparocopique dans le traitment de l&iacute;ulcere duodenal. J Chir (Paris) 1992; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/36\">",
"      Taylor TV, Lythgoe JP, McFarland JB, et al. Anterior lesser curve seromyotomy and posterior truncal vagotomy versus truncal vagotomy and pyloroplasty in the treatment of chronic duodenal ulcer. Br J Surg 1990; 77:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/37\">",
"      HELSINGEN N, HILLESTAD L. Cancer development in the gastric stump after partial gastrectomy for ulcer. Ann Surg 1956; 143:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/38\">",
"      Domell&ouml;f L, Janunger KG. The risk for gastric carcinoma after partial gastrectomy. Am J Surg 1977; 134:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/39\">",
"      Schuman BM, Waldbaum JR, Hiltz SW. Carcinoma of the gastric remnant in a U.S. population. Gastrointest Endosc 1984; 30:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/40\">",
"      Viste A, Bj&oslash;rnestad E, Opheim P, et al. Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients. Lancet 1986; 2:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/41\">",
"      Lundeg&aring;rdh G, Adami HO, Helmick C, et al. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988; 319:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/42\">",
"      Gandolfi L, Vaira D, Bertoni F, et al. Cancer of the gastric stump in Italy, 1979-1986. Gastrointest Endosc 1988; 34:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/43\">",
"      Greene FL. Gastroscopic screening of the post-gastrectomy stomach. Relationship of dysplasia to remnant cancer. Am Surg 1989; 55:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/44\">",
"      Sta&euml;l von Holstein C, Eriksson S, Huldt B, Hammar E. Endoscopic screening during 17 years for gastric stump carcinoma. A prospective clinical trial. Scand J Gastroenterol 1991; 26:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/45\">",
"      M&oslash;ller H, Toftgaard C. Cancer occurrence in a cohort of patients surgically treated for peptic ulcer. Gut 1991; 32:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/46\">",
"      Schafer LW, Larson DE, Melton LJ 3rd, et al. The risk of gastric carcinoma after surgical treatment for benign ulcer disease. A population-based study in Olmsted County, Minnesota. N Engl J Med 1983; 309:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/47\">",
"      Ross AH, Smith MA, Anderson JR, Small WP. Late mortality after surgery for peptic ulcer. N Engl J Med 1982; 307:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/48\">",
"      La Vecchia C, Negri E, D'Avanzo B, et al. Partial gastrectomy and subsequent gastric cancer risk. J Epidemiol Community Health 1992; 46:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/49\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/50\">",
"      Johnson HD. Gastric ulcer: classification, blood group characteristics, secretion patterns and pathogenesis. Ann Surg 1965; 162:996.",
"     </a>",
"    </li>",
"    <li>",
"     Jordan, PH Jr. Gastric ulcer. In: Surgery of the Stomach, Duodenum, and Small Intestine, Scott, H Jr, Sawyers, JL (Eds), Blackwell Scientific Publications, Boston, 1991, p. 309.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/52\">",
"      McDonald MP, Broughan TA, Hermann RE, et al. Operations for gastric ulcer: a long-term study. Am Surg 1996; 62:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/53\">",
"      Jordan PH Jr. Type I gastric ulcer treated by parietal cell vagotomy and mucosal ulcerectomy. J Am Coll Surg 1996; 182:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33688/abstract/54\">",
"      Tekant Y, Goh P, Low C, Ngoi SS. Pyloric channel ulcers: management and three-year follow-up. Am Surg 1995; 61:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8039 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33688=[""].join("\n");
var outline_f32_57_33688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OPERATION FOR DUODENAL ULCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vagotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Truncal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Selective",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Highly selective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastric resection procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Truncal vagotomy with antrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSTGASTRECTOMY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Postvagotomy diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dumping syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alkaline reflux gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Early satiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Afferent and efferent loop syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of operation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gastric cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OPERATION FOR GASTRIC ULCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Type I gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Type II gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Type III gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Type IV gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8039|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/32/29185\" title=\"figure 1\">",
"      Drainage procedures used with vagotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/7/15475\" title=\"figure 2\">",
"      Billroth reconstruction following gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13876\" title=\"figure 3\">",
"      Variations of Billroth II reconstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9384?source=related_link\">",
"      Acute hemorrhagic erosive gastropathy and chronic chemical gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=related_link\">",
"      Refractory or recurrent peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=related_link\">",
"      Surgical management of complications of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33689="Infiltration of local anesthetics";
var content_f32_57_33689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infiltration of local anesthetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Deborah C Hsu, MD, MEd",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Stanley J Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33689/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/57/33689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful procedures, such as skin surgery, wound repair, lumbar puncture, or the insertion of vascular catheters, are common practices that cause distress. The pain of these procedures is attenuated by infiltration of local anesthesia and, in certain patient populations (eg, young children, adults with a complicated laceration repair), procedural sedation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical anesthesia may be appropriate in some patients, such as prior to insertion of intravascular catheters (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    ). However, with surgery on intact skin, large wounds, or the need for an immediate anesthetic effect, local infiltration is necessary to safely achieve adequate analgesia.",
"   </p>",
"   <p>",
"    Most local anesthetics are classified as amides or esters (",
"    <a class=\"graphic graphic_table graphicRef57120 \" href=\"mobipreview.htm?17/47/18171\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Local anesthetics in the amide class include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (the most commonly used agent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , etidocaine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    , and levobupivacaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Common ester agents include procaine (Novocaine&reg;), 2-chloroprocaine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    , cocaine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3\">",
"     3",
"    </a>",
"    ]. Because of toxicity and allergic reactions, the ester agents have",
"    <strong>",
"     limited",
"    </strong>",
"    indications for local infiltration, except in patients with allergy to amide agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    , and procaine are the most commonly used agents for infiltration of local anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"     5",
"    </a>",
"    ]. Issues related to the choice of anesthetic and the techniques for local infiltration are reviewed here. The following related topics are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comprehensive discussion of local anesthetics, including their pharmacodynamics and pharmacokinetics",
"     </li>",
"     <li>",
"      Regional nerve blocks (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=see_link\">",
"       \"Overview of peripheral nerve blocks\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link\">",
"       \"Peripheral nerve block: Techniques\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link&amp;anchor=H15#H15\">",
"       \"Overview of anesthesia and anesthetic choices\", section on 'Peripheral nerve block'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Topical anesthetics in children (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      General approach to the management of pain and sedation in children (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuraxial analgesia and anesthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2693192\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin is made up of the epidermis and dermis. The subcutaneous layer lies beneath the dermis (",
"    <a class=\"graphic graphic_figure graphicRef54157 \" href=\"mobipreview.htm?30/11/30902\">",
"     figure 1",
"    </a>",
"    ). Direct infiltration of local anesthetic into the subcutaneous layer effectively blocks pain transmission from the free nerve endings located in the epidermal and dermal layers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/6\">",
"     6",
"    </a>",
"    ]. Intradermal injection is also effective but more painful than subcutaneous injection. &nbsp;",
"   </p>",
"   <p>",
"    Local anesthetics reversibly block sodium channels within the nerve fibers, which prevents transmission of pain signals by disrupting depolarization of the nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3\">",
"     3",
"    </a>",
"    ]. Pain fibers are relatively unmyelinated when compared to afferent fibers that transmit the sensation of touch or temperature or nerves that control muscle contraction. Thus, infiltration of dilute solutions of local anesthetics near the nerve fibers produces relief of pain with less interruption in the sense of touch or temperature and without muscle paralysis in most children and adults. Because myelin sheaths throughout the nervous system are not fully developed in neonates and young infants, even dilute solutions of local anesthetics have a higher potential for producing muscle paralysis and central toxicity in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local anesthetics are weak organic bases that are composed of charged and uncharged ions when in solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Only the uncharged ions are thought to be capable of diffusion through interstitial tissues and transport across the nerve membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/10\">",
"     10",
"    </a>",
"    ]. Dispersion of the local anesthetic through the tissue occurs more rapidly as the percentage of uncharged ion increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/8\">",
"     8",
"    </a>",
"    ]. The pH of the solution and the surrounding tissues and the pKa of the specific agent determine the proportion of charged and uncharged anesthetic. Increased acidity of the solution or of the tissues (eg, infected skin) reduces the proportion of anesthetic in the uncharged form according to Henderson-Hasselbach equation as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [Charged anesthetic] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(pKa-pH)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;___________________ = 10",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [Uncharged anesthetic]",
"   </p>",
"   <p>",
"    Most local anesthetic solutions are marketed in acidic forms with pH of 5.0 to 7.0. The anesthetic is more stable in this pH range and has a shelf life of three to four years at room temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/8\">",
"     8",
"    </a>",
"    ]. For some formulations, the pH of the anesthetic solution is increased to 7.2 to 7.4 (physiologic pH) by the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . This results in a greater proportion of anesthetic being in the uncharged form, thereby enhancing the analgesic effect and decreasing the pain of injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/7,8,11\">",
"     7,8,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H540550\">",
"     'Methods to decrease injection pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, once the pH is increased, the buffered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is more susceptible to photodegradation, aldehyde formation, and other denaturing reactions, leading to a shelf life of one to three weeks at room temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. This buffering approach cannot be used for some agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) because they will precipitate at physiologic pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2693871\">",
"    <span class=\"h1\">",
"     CHOICE OF ANESTHETIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The comparative properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , procaine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    are provided in the table and can affect the choice of anesthetic in particular situations (",
"    <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"     table 2",
"    </a>",
"    ). A history of allergy to specific anesthetics or specific additives (eg, methylparaben, metabisulfite) contained in different formulations of the same anesthetic may also impact the choice of agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    is a local anesthetic in the amide class and is the most commonly used anesthetic for local infiltration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preparation",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      is usually given as a 1 percent solution (10",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"      If large volumes are needed or a smaller dose is desired, the clinician may use a 0.5 percent solution. Higher concentrations of lidocaine beyond 1 percent do not promote improved onset or duration of analgesia and may increase the risk of toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"       5",
"      </a>",
"      ]. Buffering of lidocaine with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (as described in the preceding section) decreases the pain of injection, especially when using lidocaine with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , and may shorten the time to anesthetic effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H540550\">",
"       'Methods to decrease injection pain'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &ndash; The dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      should",
"      <strong>",
"       not exceed",
"      </strong>",
"      the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/9,13\">",
"       9,13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      WITHOUT",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      (also called plain lidocaine) &ndash; 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of lidocaine 1 percent, maximum total dose: 300 mg [30 mL of lidocaine 1 percent])",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      WITH",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.7",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of lidocaine 1 percent, maximum total dose: 500 mg [50 mL of lidocaine 1 percent with epinephrine]).",
"      <br/>",
"      <br/>",
"      For an added margin of safety, 80 percent of the maximum allowable dose should be used in children under eight years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, because anesthetics in the amide class are metabolized by the liver and excreted by the kidneys, the total dose of lidocaine should be decreased by approximately 50 percent in elderly patients with severe liver or kidney disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/11,14\">",
"       11,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Onset of action and duration of anesthesia",
"      </strong>",
"      &ndash; The onset of anesthesia typically occurs within two to five minutes, and the duration of anesthesia varies from 30 minutes to two hours for plain",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , which is long enough to complete most procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/11,15,16\">",
"       11,15,16",
"      </a>",
"      ]. The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      (available premixed at concentrations of 1:100,000 or 1:200,000) provides local vasoconstriction which prolongs the duration of action (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"       table 2",
"      </a>",
"      ), decreases local bleeding during the procedure, and reduces systemic lidocaine absorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/15\">",
"       15",
"      </a>",
"      ]. In addition, this combination may extend the duration of anesthesia up to three hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The concentration of epinephrine may be diluted to less than 1:200,000 by mixing plain lidocaine and lidocaine with epinephrine in patients who are sensitive to catecholamine injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"       16",
"      </a>",
"      ]. Concentrations as low as 1:1,000,000 still maintain effective vasoconstriction. However, this dilution does decrease the duration of action, may allow for greater systemic absorption, and may increase the amount of local bleeding. (See",
"      <a class=\"local\" href=\"#H2694354\">",
"       'Catecholamine sensitivity'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Lidocaine with epinephrine may be used in the face (including the nose and ear), digit, or penis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"       16",
"      </a>",
"      ]. In the past, injection of epinephrine with local anesthetic was discouraged in these sites. However, there is no convincing evidence of harm with such use. As an example, comprehensive reviews of the medical literature and large observational studies have failed to find any reports of gangrene or major ischemic complications solely attributable to lidocaine with epinephrine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link&amp;anchor=H6#H6\">",
"       \"Digital nerve block\", section on 'Use of epinephrine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    should be",
"    <strong>",
"     avoided",
"    </strong>",
"    for digital anesthesia in patients with peripheral artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2694370\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bupivacaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    is an amide anesthetic that is more potent and has a longer duration of action than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    , or procaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The increases in potency and duration of action are related to prolonged binding of sodium channels. Thus, if systemically absorbed, bupivacaine has a higher risk of major toxicity (eg, seizures, intractable cardiac arrhythmias) than lidocaine and most other local anesthetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/7\">",
"     7",
"    </a>",
"    ]. Bupivacaine is contraindicated for local infiltration in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], and should be infiltrated with caution in acutely ill, debilitated, or elderly patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    is a good choice for longer procedures, for patients who have contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    injection, for situations where there will be a delay between infiltration of local anesthetic and the procedure, or for instances in which prolonged post-procedure pain control is preferred.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preparation",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       Bupivacaine",
"      </a>",
"      is commercially available in concentrations of 0.25 percent (2.5",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      and 0.5 percent (5",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"      The lower concentration should be used in awake patients because local infiltration with 0.5 percent bupivacaine is painful. Unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , buffering with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      does not reduce the pain of injection and may lead to precipitation of the active drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H540550\">",
"       'Methods to decrease injection pain'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &ndash; The dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      <strong>",
"       exceed",
"      </strong>",
"      the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       Bupivacaine",
"      </a>",
"      WITHOUT",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.8",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of bupivacaine 0.25 percent, maximum total dose: 175 mg [70 mL of bupivacaine 0.25 percent])",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       Bupivacaine",
"      </a>",
"      WITH",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (1.2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of bupivacaine 0.25 percent, maximum total dose: 225 mg [90 mL of bupivacaine 0.25 percent with epinephrine])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Onset of action and duration of anesthesia",
"      </strong>",
"      &ndash; The onset of action of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      is 5 to 10 minutes and the duration of effect is up to six hours (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"       5",
"      </a>",
"      ]. The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      does not increase the duration of anesthetic effect but may decrease systemic absorption, and use may be desirable for hemostatic purposes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3,7\">",
"       3,7",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694061\">",
"    <span class=\"h2\">",
"     Mepivacaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     Mepivacaine",
"    </a>",
"    , an amide local anesthetic, is an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , although it is less commonly used. Systemic toxicity is similar to that of lidocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Pregnancy is a relative contraindication to the use of mepivacaine because of poor fetal metabolism related to hepatic immaturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preparation",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       Mepivacaine",
"      </a>",
"      is usually administered as a 1 percent (10",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      solution. A 0.5 percent (5",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      solution is also commercially available.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &ndash; The dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       mepivacaine",
"      </a>",
"      should",
"      <strong>",
"       not exceed",
"      </strong>",
"      the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"       16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       Mepivacaine",
"      </a>",
"      WITHOUT",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of mepivacaine 1 percent, maximum total dose 300 mg [30",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of mepivacaine 1 percent]) &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       Mepivacaine",
"      </a>",
"      WITH",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.7",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of mepivacaine 1 percent, maximum total dose 500 mg [50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of mepivacaine 1 percent with epinephrine])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Onset of action and duration of anesthesia",
"      </strong>",
"      &ndash; Similar to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       mepivacaine",
"      </a>",
"      has an onset of action of two to five minutes and duration of anesthesia lasting up to two hours. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. Addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      increases the duration of action up to three hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/2,16\">",
"       2,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2693989\">",
"    <span class=\"h2\">",
"     Procaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procaine (Novacaine&reg;) is an ester anesthetic. Its primary use is in patients undergoing dental procedures and those with allergy to amide anesthetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"     5",
"    </a>",
"    ]. When compared to lidocaine, procaine has a longer time to onset of action, shorter duration of action, and poor penetrating ability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/7\">",
"     7",
"    </a>",
"    ]. However, it has very little systemic toxicity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preparation",
"      </strong>",
"      &ndash; Procaine is typically administered as a 1 percent (10",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      solution. A 0.5 percent (5",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      solution is also commercially available.",
"     </li>",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &ndash; The dose of procaine should",
"      <strong>",
"       not exceed",
"      </strong>",
"      the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5,16\">",
"       5,16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Procaine WITHOUT",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.7",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of procaine 1 percent, maximum total dose 500 mg [50 mL of procaine 1 percent])",
"     </li>",
"     <li>",
"      Procaine WITH",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &ndash; 9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.9",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of procaine 1 percent, maximum total dose 600 mg [60 mL of procaine 1 percent with epinephrine])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Onset of action and duration of anesthesia",
"      </strong>",
"      &ndash; Procaine has an onset of action of 5 to 10 minutes and duration of anesthesia of up to 1.5 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694362\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration of local anesthesia is effective for pain control during a variety of procedures, including skin surgery (eg, skin biopsy, scar revision, small skin grafts), open wound repair, abscess drainage, foreign body removal from the skin, vascular access procedures, and lumbar puncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ]. The choice of agent depends on several factors, including the duration of the procedure, need for hemostasis, patient sensitivity to catecholamines, and patient allergy to local anesthetics (",
"    <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2693871\">",
"     'Choice of anesthetic'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In children, we suggest initial pain control with topical LET (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    ) rather than infiltrative anesthesia for uncomplicated facial or scalp lacerations. Children should also receive some form of topical analgesia prior to nonemergent venipuncture, intravenous catheter placement, or Port-A-Cath access. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H2#H2\">",
"     \"Topical anesthetics in children\", section on 'LET'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H46#H46\">",
"     \"Topical anesthetics in children\", section on 'Venipuncture, intravenous catheter placement, or Port-A-Cath access'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694370\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;True allergy to a local anesthetic is a contraindication for use of that anesthetic and other agents with the same chemical classification (ie, amide or ester) (",
"    <a class=\"graphic graphic_table graphicRef57120 \" href=\"mobipreview.htm?17/47/18171\">",
"     table 1",
"    </a>",
"    ). In contrast, local administration of an anesthetic with a different chemical classification is safe in most instances, as long as prior administration was not associated with generalized urticaria or anaphylaxis. If the procedure is elective, it is optimal to have the patient evaluated by an allergist prior to the procedure to assist in distinguishing allergy to the local anesthetic from allergy to other chemical additives (eg, methylparaben) and to help differentiate an allergic reaction from other types of adverse reactions commonly associated with infiltration of local anesthetics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H19#H19\">",
"     \"Allergic reactions to local anesthetics\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H24#H24\">",
"     \"Allergic reactions to local anesthetics\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H14#H14\">",
"     \"Allergic reactions to local anesthetics\", section on 'Mimics of allergic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infiltration of local anesthetics is not recommended for the management of large or multiple lacerations where the total dose needed for adequate effect is expected to be close to the maximum allowable anesthetic dose (",
"    <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"     5",
"    </a>",
"    ]. In such situations, a regional block or Bier (IV regional) block may be performed instead.",
"   </p>",
"   <p>",
"    A regional block may be preferable to infiltration of local anesthetic for repair of wounds that require precise anatomic alignment (eg, lacerations through the vermillion border of the lip) because local infiltration might distort important skin landmarks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should",
"    <strong>",
"     not",
"    </strong>",
"    use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    with local anesthetic infiltration in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large wounds in patients with underlying conditions (eg, hyperthyroidism, pheochromocytoma, severe hypertension, coronary artery disease) that may be exacerbated by systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      effects.",
"     </li>",
"     <li>",
"      Digital anesthesia in patients with peripheral artery disease",
"     </li>",
"     <li>",
"      Periorbital infiltration in patients with narrow angle glaucoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    infiltration with local anesthetics should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in the following patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients receiving beta blockers, monoamine oxidase inhibitors, phenothiazines, or tricyclic antidepressants",
"     </li>",
"     <li>",
"      Patients with catecholamine sensitivity (see",
"      <a class=\"local\" href=\"#H2694354\">",
"       'Catecholamine sensitivity'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694386\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should determine the patient&rsquo;s prior experience with local anesthesia and if allergies or adverse reactions have occurred. The patient and family should receive an explanation of the planned approach. A child life specialist or other personnel are often helpful in reducing the anxiety of children undergoing painful procedures. Procedural sedation may be necessary in addition to infiltration of local anesthesia for certain patients (eg, young children or anxious older patients) who are undergoing cosmetic laceration repairs or other procedures (eg, central venous access, lumbar puncture) that require complete patient cooperation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343901\">",
"    <span class=\"h2\">",
"     History of adverse reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical situations may arise in which local anesthesia is required for a patient with a history of a prior adverse reaction to a specific local anesthetic. True IgE-mediated allergic reactions to local anesthetic agents are rare, but convincing case reports do exist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H12#H12\">",
"     \"Allergic reactions to local anesthetics\", section on 'Urticaria and anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a local anesthetic is needed in a patient with a past adverse reaction, the patient's past signs and symptoms should be reviewed along with any procedures that were performed with local anesthesia since the adverse reaction (eg, dental procedures). If the reaction can be specifically identified as something other than allergy (eg, catecholamine sensitivity, systemic toxicity, vasovagal syncope), then the clinician should focus on strategies that specifically limit anxiety, pain, total dose of anesthetic administered, or catecholamine exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H14#H14\">",
"     \"Allergic reactions to local anesthetics\", section on 'Mimics of allergic reactions'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H540550\">",
"     'Methods to decrease injection pain'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2\">",
"     'Lidocaine'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H26#H26\">",
"     \"Allergic reactions to local anesthetics\", section on 'Patients with past nonallergic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the reaction consists of contact dermatitis or delayed local swelling, it is reasonable to proceed with the use of a local anesthetic from the",
"    <strong>",
"     other",
"    </strong>",
"    group (ester or amide) (",
"    <a class=\"graphic graphic_table graphicRef57120 \" href=\"mobipreview.htm?17/47/18171\">",
"     table 1",
"    </a>",
"    ). In most cases, patients with type IV allergic reactions are tolerant of a local anesthetic chosen from the group of agents to which they did not react. As an example, a patient with past possible allergy to procaine (group I) would be predicted to tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (group II) in most cases. In addition, it is prudent to use a preservative-free formulation that does not contain metabisulfites or methylparaben in patients with type IV allergic reactions to local anesthetics. Patch testing prior to the procedure is ideal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H10#H10\">",
"     \"Allergic reactions to local anesthetics\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who report a history of symptoms that are suggestive of anaphylaxis (ie, diffuse hives, wheezing, throat closure) or any other life-threatening reaction should",
"    <strong>",
"     not",
"    </strong>",
"    receive local anesthetics until they undergo a complete evaluation by an allergy specialist. If the procedure is elective, it should be deferred until this evaluation has occurred. If the procedure is urgent, then the patient should receive an alternative to local anesthesia (eg, procedural sedation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of possible allergy to local anesthetics is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link\">",
"     \"Allergic reactions to local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540456\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should assemble the following items:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Povidone-iodine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      solution",
"     </li>",
"     <li>",
"      Sterile gauze",
"     </li>",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      25-, 27-, or 30-gauge long (1.5 inch) hypodermic needle",
"     </li>",
"     <li>",
"      Syringe (1 ,3, 5, 6, or 10 mL)",
"     </li>",
"     <li>",
"      Local anesthetic agent (see",
"      <a class=\"local\" href=\"#H2693871\">",
"       'Choice of anesthetic'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694394\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540550\">",
"    <span class=\"h2\">",
"     Methods to decrease injection pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is used for local anesthesia during urgent or nonemergent procedures, we suggest buffering with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . A meta-analysis of 23 trials that compared pain during subcutaneous infiltration of pH-adjusted or unadjusted lidocaine in children and adults found that patients receiving buffered lidocaine reported significantly less pain than those who received unbuffered lidocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/18\">",
"     18",
"    </a>",
"    ]. The decrease in pain was greater for patients who received lidocaine with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    but was also evident for patients who received plain lidocaine. In eight crossover studies included in the meta-analysis, patients reported that they preferred buffered lidocaine (OR 3.0, 95% CI 1.2-4.2). There was significant heterogeneity of the results that was not explained by risk of bias in individual studies, the amount of lidocaine injected, or the type of procedure performed.",
"   </p>",
"   <p>",
"    The standard solutions of plain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or commercially prepared lidocaine with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    have pH values of 5.0 to 7.0 and 3.0 to 5.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. These preparations can be buffered by adding one part of 1",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    to 9 or 10 parts of 1 percent lidocaine or lidocaine with epinephrine. The shelf life of buffered plain lidocaine is approximately one week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the addition of bicarbonate to lidocaine with epinephrine inactivates epinephrine within 24 hours. Thus, when using multidose vials of lidocaine, it is best to buffer it by drawing the appropriate volumes of sodium bicarbonate and lidocaine into the syringe rather than injecting sodium bicarbonate into the vial.",
"   </p>",
"   <p>",
"    Several other techniques may decrease the pain associated with injection. They include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/5,6,16\">",
"     5,6,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient distraction (eg, television, mental imagery, and in children, books or toys [eg, pinwheel, blowing bubbles])",
"     </li>",
"     <li>",
"      Gentle pinching or vibration adjacent to the site of injection",
"     </li>",
"     <li>",
"      Use of small needles (25-, 27-, or 30-gauge)",
"     </li>",
"     <li>",
"      Slow rate of injection",
"     </li>",
"     <li>",
"      Subcutaneous instead of intradermal injection",
"     </li>",
"     <li>",
"      Warming of local anesthetic to body temperature prior to injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reducing pressure of injection by using small volume syringes (eg, 1 or 3 mL)",
"     </li>",
"     <li>",
"      Injecting with a needle angle of 90 rather than 45 degrees when penetrating intact skin for elective procedures (eg, skin biopsy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343150\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intact, uninfected skin and clean lacerations may undergo direct infiltration. Heavily contaminated lacerations or skin abscesses should undergo a field block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343175\">",
"    <span class=\"h3\">",
"     Direct infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps for direct infiltration of local anesthetic are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For lacerations, ensure that the areas distal to the wound show no neurovascular compromise.",
"     </li>",
"     <li>",
"      Explain the procedure to the patient and, in children, the caregiver.",
"     </li>",
"     <li>",
"      Provide sedation and restraint, as needed (eg, children or other potentially uncooperative patients). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cleanse the site of infiltration with povidone-iodine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      solution or other similar antiseptic preparation and allow to air dry or dry with sterile gauze.",
"     </li>",
"     <li>",
"      Hide the needle from view prior to and during injection, especially in children.",
"     </li>",
"     <li>",
"      For open wounds, put a few drops of anesthetic into the wound and then rapidly place the needle into the subcutaneous layer (",
"      <a class=\"graphic graphic_figure graphicRef54157 \" href=\"mobipreview.htm?30/11/30902\">",
"       figure 1",
"      </a>",
"      ) by inserting it through the wound margin rather than intact skin.",
"     </li>",
"     <li>",
"      For intact skin, rapidly place the needle through the skin into the subcutaneous layer (",
"      <a class=\"graphic graphic_figure graphicRef54157 \" href=\"mobipreview.htm?30/11/30902\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Slowly inject small volumes of anesthetic. During anesthetic infiltration, either slowly advance the needle or initially insert it to the hub and infiltrate as the needle is withdrawn. Aspiration is not necessary prior to each infiltration unless the area undergoing local anesthesia is close to major blood vessels.",
"     </li>",
"     <li>",
"      Anesthetize adjacent areas by inserting the needle through the previously injected skin or wound until the entire region requiring anesthesia is infiltrated. This is ordinarily accomplished in a linear laceration, for example, by entering the proximal portion of the wound and administering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      as one proceeds forward or by moving the needle forward to the distal end of the wound and withdrawing back to the original point while injecting lidocaine. The physician or healthcare provider should understand where the last portion of anesthesia was delivered and insert the needle in that area if additional injections are required. This will avoid additional pain from repeated insertion of the needle.",
"     </li>",
"     <li>",
"      After a few minutes, lightly test the skin or wound margins for adequate anesthesia using the injection needle or other sharp object (suture needle, Adson forceps). Timing of complete and optimal anesthesia will depend upon the local anesthetic that is used (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"       table 2",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343182\">",
"    <span class=\"h3\">",
"     Field block",
"    </span>",
"    &nbsp;&mdash;&nbsp;For heavily contaminated wounds or when anesthetizing for incision and drainage of a skin abscess, prepare the patient and wound in the same way as for direct infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H343175\">",
"     'Direct infiltration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Procedural sedation may also be necessary to ensure proper wound decontamination in a relatively painless manner. Alternatively, a regional block may be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=see_link\">",
"     \"Overview of peripheral nerve blocks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proceed with the field block as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the needle into the subcutaneous layer through intact, clean skin along the margin of the contaminated wound or through uninfected skin immediately adjacent to the abscess.",
"     </li>",
"     <li>",
"      Slowly inject small volumes of anesthetic taking care to monitor the total dose administered. During anesthetic infiltration, either slowly advance the needle or initially insert it to the hub, and infiltrate as the needle is withdrawn. Aspiration is not necessary prior to each infiltration, unless the area undergoing local anesthesia is close to major blood vessels.",
"     </li>",
"     <li>",
"      Reinsert the needle through the area just anesthetized, redirecting it along the margins of the wound or circumferentially around the abscess and infiltrate additional anesthetic.",
"     </li>",
"     <li>",
"      Continue infiltration through previously injected skin until the entire region requiring anesthesia is infiltrated.",
"     </li>",
"     <li>",
"      After a few minutes, lightly test the skin or wound margins for adequate anesthesia using the injection needle or other sharp object (suture needle, Adson forceps). Timing of complete and optimal anesthesia will depend upon the local anesthetic that is used (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"       table 2",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694410\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient, and in children, the caretaker, should be advised that full recovery of sensation in the anesthetized region is expected soon after the procedure. The exact timing of recovery will depend upon the anesthetic used (",
"    <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"     table 2",
"    </a>",
"    ). Until full sensation has returned, the patient should be told that the region is prone to inadvertent injury, including thermal injury from excessive heat or cold exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications during infiltration of local anesthetics are rare. Avoidance of intravascular injection into major vessels and care not to exceed the maximum total dose of anesthetic helps to avoid complications in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694642\">",
"    <span class=\"h2\">",
"     Systemic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic toxicity, such as central nervous system (CNS) and cardiovascular symptoms, is an unusual event, but can occur if the recommended dose is exceeded, if a major vessel is inadvertently injected with a large amount of anesthetic, or as an idiosyncratic response. Among the local anesthetics commonly infiltrated,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    has the greatest potential for systemic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3,7,22\">",
"     3,7,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CNS effects include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metallic taste",
"     </li>",
"     <li>",
"      Tinnitus",
"     </li>",
"     <li>",
"      Tingling of the lips",
"     </li>",
"     <li>",
"      Agitation",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures are dose dependent and more likely to occur in patients with predisposing underlying conditions, hypercarbia, or hypoxemia. Patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    toxicity typically have initial CNS findings of altered taste, paresthesias, or agitation; in contrast, patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    toxicity often have seizures as the first manifestation of toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Seizures due to local anesthetic toxicity are typically brief. Initial treatment consists of oxygenation, airway support, and administration of a benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.05",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiovascular side effects include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bradycardia",
"     </li>",
"     <li>",
"      Decreased myocardial contractility",
"     </li>",
"     <li>",
"      Atrioventricular block",
"     </li>",
"     <li>",
"      Vasodilation",
"     </li>",
"     <li>",
"      Ventricular arrhythmias",
"     </li>",
"     <li>",
"      Cardiac arrest",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14845728\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias and cardiogenic shock should be initially treated according to standard protocols (",
"    <a class=\"graphic graphic_table graphicRef54328 \" href=\"mobipreview.htm?12/6/12397\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"mobipreview.htm?20/4/20545\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"mobipreview.htm?11/37/11860\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"mobipreview.htm?41/12/42178\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based upon case reports, patients with local anesthetic toxicity who are in cardiac arrest or have severe, refractory arrhythmias (eg, ventricular tachycardia) may benefit from administration of intravenous fat emulsions. The suggested dose is a bolus of 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 20% IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/29/17878?source=see_link\">",
"     fat emulsion",
"    </a>",
"    followed by a continuous infusion at a rate of 0.25",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    until full hemodynamic recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. &nbsp;If after 30 minutes there is no clinical improvement, the bolus dose of 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    should be repeated and the continuous infusion should be increased to 0.5",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     Bupivacaine",
"    </a>",
"    toxicity may lead to prolonged and refractory arrhythmia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension requiring one to two hours of cardiopulmonary resuscitation before redistribution from the heart and recovery of cardiac function occurs. Extracorporeal membrane oxygenation may permit preserved tissue oxygenation and perfusion in patients with this severe degree of toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694354\">",
"    <span class=\"h2\">",
"     Catecholamine sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia, hypertension, palpitations, and anxiety (eg, a sense of doom) may accompany subcutaneous injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in sensitive patients or inadvertent intravascular injection in normal patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33689/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345706\">",
"    <span class=\"h2\">",
"     Vasovagal syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasovagal (also called neurocardiogenic) syncope is usually associated with bradycardia (rather than tachycardia) and pallor (rather than flushing). These differences can be helpful in distinguishing it from anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=see_link&amp;anchor=H9#H9\">",
"     \"Reflex syncope\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344652\">",
"    <span class=\"h2\">",
"     Allergic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different types of allergic reactions to local anesthetics have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic contact dermatitis and delayed swelling at the site of administration &ndash; Affected patients develop a localized eczematous and pruritic rash within 72 hours at the site of local anesthetic administration. Vesiculation, blistering,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weeping can occur. The affected area is limited to tissue that was in direct contact with the anesthetic. Treatment is as for other types of contact dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link&amp;anchor=H8#H8\">",
"       \"Contact dermatitis in children\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H3#H3\">",
"       \"Allergic reactions to local anesthetics\", section on 'Contact dermatitis or delayed local swelling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urticaria and anaphylaxis &ndash; These types of reaction are rare and the data implicating local anesthetics are limited to case reports. Patients who display signs of acute anaphylaxis (eg, hives, facial or intraoral swelling, stridor, wheezing, hypotension) (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 4",
"      </a>",
"      ) should receive emergent treatment (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H12#H12\">",
"       \"Allergic reactions to local anesthetics\", section on 'Urticaria and anaphylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/42/6818?source=see_link\">",
"       \"Patient information: Anesthesia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2694419\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltration of local anesthesia is effective for pain control during a variety of procedures, including skin surgery (eg, skin biopsy, scar revision, small skin grafts), open wound repair, abscess drainage, foreign body removal from the skin, vascular access procedures, and lumbar puncture. (See",
"      <a class=\"local\" href=\"#H2694362\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of local anesthetic for infiltration depends on several factors, including duration of the procedure, need for hemostasis, patient sensitivity to catecholamines, and patient allergy to local anesthetics (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"       table 2",
"      </a>",
"      ). For most procedures and for most patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      is a good choice. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lidocaine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2693871\">",
"       'Choice of anesthetic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to infiltration, the clinician should determine if the patient has any history of allergy or adverse reaction associated with receiving local anesthesia. Most patients with a prior adverse reaction can still undergo infiltration of local anesthesia with adjustments in the agent or formulation that is used. (See",
"      <a class=\"local\" href=\"#H343901\">",
"       'History of adverse reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a true allergic reaction to a local anesthetic warrant evaluation by an allergy specialist. (See",
"      <a class=\"local\" href=\"#H343901\">",
"       'History of adverse reaction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link\">",
"       \"Allergic reactions to local anesthetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local anesthetic infiltration is contraindicated in the following instances (see",
"      <a class=\"local\" href=\"#H2694370\">",
"       'Contraindications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The amount of anesthetic needed to provide adequate analgesia exceeds the maximal safe total dose.",
"     </li>",
"     <li>",
"      The patient has had generalized urticaria or anaphylaxis in association with administration of local anesthesia and has not undergone evaluation by an allergy subspecialist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When local anesthetics are used during urgent or nonemergent procedures, we suggest warming the anesthetic agent to approximately body temperature (37&deg;C) prior to injection (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H540550\">",
"       'Methods to decrease injection pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      is used for local anesthesia during urgent or nonemergent procedures, we suggest buffering with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Buffering of lidocaine is of particular benefit for children or when injecting lidocaine with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H540550\">",
"       'Methods to decrease injection pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other techniques to reduce the pain of injection may also be successful. (See",
"      <a class=\"local\" href=\"#H540550\">",
"       'Methods to decrease injection pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The techniques for direct infiltration of local anesthetics and field block are described. (See",
"      <a class=\"local\" href=\"#H343150\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30532439\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/1\">",
"      Achar S, Kundu S. Principles of office anesthesia: part I. Infiltrative anesthesia. Am Fam Physician 2002; 66:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/2\">",
"      Ahlstrom KK, Frodel JL. Local anesthetics for facial plastic procedures. Otolaryngol Clin North Am 2002; 35:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/3\">",
"      Tetzlaff JE. The pharmacology of local anesthetics. Anesthesiol Clin North America 2000; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/4\">",
"      Giovannitti JA, Bennett CR. Assessment of allergy to local anesthetics. J Am Dent Assoc 1979; 98:701.",
"     </a>",
"    </li>",
"    <li>",
"     McGee, DL. Local and topical anesthesia. In: Clinical Procedures In Emergency Medicine, 5th edition, Roberts, JR, Hedges, JR (Eds), Saunders Elsevier, Philadelphia 2010. p.481.",
"    </li>",
"    <li>",
"     McCreight, A, Stephan, M. Local and regional anesthesia. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King, C, Henretig, FM (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2008. p.439.",
"    </li>",
"    <li>",
"     Yaster, M, Tobin, JR, Kost-Byerly, S. Local anesthetics. In: Pain In Infants, Children, And Adolescents, 2nd edition, Schechter, NL, Berde, CB, Yaster, M (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA 2003. p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/8\">",
"      Christoph RA, Buchanan L, Begalla K, Schwartz S. Pain reduction in local anesthetic administration through pH buffering. Ann Emerg Med 1988; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/9\">",
"      Berde CB. Toxicity of local anesthetics in infants and children. J Pediatr 1993; 122:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/10\">",
"      Ritchie JM, Ritchie B, Greengard P. The active structure of local anesthetics. J Pharmacol Exp Ther 1965; 150:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/11\">",
"      Stanton-Hicks, MD.  Local anesthetics: Pharmacology and clinical applications. Hosp Formul 1987; 22:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/12\">",
"      Bartfield JM, Homer PJ, Ford DT, Sternklar P. Buffered lidocaine as a local anesthetic: an investigation of shelf life. Ann Emerg Med 1992; 21:16.",
"     </a>",
"    </li>",
"    <li>",
"     Selbst SM, Fein JA. Sedation and analgesia. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/14\">",
"      Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007; 46:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/15\">",
"      Kennedy RM, Luhmann JD. The \"ouchless emergency department\". Getting closer: advances in decreasing distress during painful procedures in the emergency department. Pediatr Clin North Am 1999; 46:1215.",
"     </a>",
"    </li>",
"    <li>",
"     Hruza, GJ. Anesthesia. In: Dermatology, Volume 2, 2nd, Bolognia, JL, Jorizzo, JL, Rapini, RP (Eds), Mosby Elsevier, Spain 2008. p.2173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/17\">",
"      Carraccio C, Feinberg P, Hart LS, et al. Lidocaine for lumbar punctures. A help not a hindrance. Arch Pediatr Adolesc Med 1996; 150:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/18\">",
"      Cepeda MS, Tzortzopoulou A, Thackrey M, et al. Adjusting the pH of lidocaine for reducing pain on injection. Cochrane Database Syst Rev 2010; :CD006581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/19\">",
"      Mader TJ, Playe SJ, Garb JL. Reducing the pain of local anesthetic infiltration: warming and buffering have a synergistic effect. Ann Emerg Med 1994; 23:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/20\">",
"      Colaric KB, Overton DT, Moore K. Pain reduction in lidocaine administration through buffering and warming. Am J Emerg Med 1998; 16:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/21\">",
"      Martires KJ, Malbasa CL, Bordeaux JS. A randomized controlled crossover trial: lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle. J Am Acad Dermatol 2011; 65:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/22\">",
"      Moore DC, Bridenbaugh LD, Thompson GE, et al. Bupivacaine: a review of 11,080 cases. Anesth Analg 1978; 57:42.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz, DR, Kaufman, B. Anesthetics and related medications. In: Goldfranks Toxicologic Emergencies, 9th edition, Nelson, LS, Lewin, NA, Howland, MA, Hoffman, RS, Goldfrank, LR, Flomenbaum, NE (Eds), McGraw Hill, New York 2011. p.965.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/24\">",
"      Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia 2006; 61:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/25\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006; 105:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/26\">",
"      Warren JA, Thoma RB, Georgescu A, Shah SJ. Intravenous lipid infusion in the successful resuscitation of local anesthetic-induced cardiovascular collapse after supraclavicular brachial plexus block. Anesth Analg 2008; 106:1578.",
"     </a>",
"    </li>",
"    <li>",
"     Bania, TC. Intravenous fat emulsions. In: Goldfrank's Toxicologic Emergencies, 9th edition, Nelson, LS, Lewin, NA, Howland, MA, Hoffman, RS, Goldfrank, LR, Flomenbaum, NE (Eds), McGraw Hill , New York 2011. p.976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33689/abstract/28\">",
"      Weinberg G. Lipid rescue resuscitation from local anaesthetic cardiac toxicity. Toxicol Rev 2006; 25:139.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6324 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33689=[""].join("\n");
var outline_f32_57_33689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2694419\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2693192\">",
"      ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2693871\">",
"      CHOICE OF ANESTHETIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bupivacaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2694061\">",
"      Mepivacaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2693989\">",
"      Procaine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694362\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694370\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694386\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343901\">",
"      History of adverse reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H540456\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694394\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H540550\">",
"      Methods to decrease injection pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343150\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H343175\">",
"      - Direct infiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H343182\">",
"      - Field block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694410\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2694642\">",
"      Systemic toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14845728\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2694354\">",
"      Catecholamine sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345706\">",
"      Vasovagal syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344652\">",
"      Allergic reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2694419\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30532439\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6324|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?20/4/20545\" title=\"algorithm 1\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/37/11860\" title=\"algorithm 2\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/12/42178\" title=\"algorithm 3\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6324|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/11/30902\" title=\"figure 1\">",
"      Skin anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6324|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/47/18171\" title=\"table 1\">",
"      Classification local anesthetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/56/26509\" title=\"table 2\">",
"      Comparison of commonly infiltrated local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/6/12397\" title=\"table 3\">",
"      ACC AHA therapy VT VF MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 4\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16813\" title=\"table 5\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 6\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/42/6818?source=related_link\">",
"      Patient information: Anesthesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33690="Treatment of hyperphosphatemia in chronic kidney disease";
var content_f32_57_33690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hyperphosphatemia in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     L Darryl Quarles, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/57/33690/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/57/33690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tendency toward phosphate retention begins early in renal disease, due to the reduction in the filtered phosphate load. Although this problem is initially mild with hyperphosphatemia being a relatively late event, phosphate retention is intimately related to the common development of cardiovascular disease risk in CKD, increased fibroblast growth factor (FGF)-23 levels, and secondary hyperparathyroidism (",
"    <a class=\"graphic graphic_figure graphicRef68602 \" href=\"mobipreview.htm?28/43/29373\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. These adaptive endocrine alterations are a potential concern because high circulating levels of parathyroid hormone (PTH) play an important role in the development of renal osteodystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ], and elevated circulating FGF-23 concentrations are strongly associated with increased cardiovascular mortality and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From the viewpoint of calcium and phosphate balance, the hypersecretion of FGF-23 and PTH reflect the development of phosphate retention, and are initially appropriate. FGF-23 appears to be the initial hormonal abnormality leading to increased urinary phosphate excretion and suppression of 1,25(OH)2D. PTH increases in response to reductions in 1,25(OH)2D. By increasing bone turnover and calcium phosphate release from bone and enhancing urinary phosphate excretion (via a decrease in proximal reabsorption), PTH can correct both the hypocalcemia and the hyperphosphatemia. FGF-23 is also important in the renal adaptation to maintain phosphate excretion. The effect on renal phosphate handling is manifested by a progressive reduction in the fraction of the filtered phosphate that is reabsorbed, from the normal value of 80 to 95 percent to as low as 15 percent in advanced renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, phosphate balance and a normal serum phosphate concentration are generally maintained (at the price of elevated FGF-23 and hyperparathyroidism) until the glomerular filtration rate (GFR) falls below 25 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At this relatively late stage, dietary phosphate restriction may still reduce the serum concentration of phosphate, FGF-23, and PTH, although not usually to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. As a result, oral phosphate binders are frequently required. This problem is exacerbated once maintenance dialysis is required; in this setting, there is essentially no phosphate excretion and oral phosphate binders must be given to limit phosphate absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, levels of FGF-23 become extremely elevated, and the secondary hyperparathyroidism may contribute to the hyperphosphatemia by continuing to enhance the release of calcium phosphate from bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperphosphatemia alone or in combination with a high serum calcium is associated with increased mortality in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This relationship also exists in patients with less advanced kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=see_link&amp;anchor=H22#H22\">",
"     \"Patient survival and maintenance dialysis\", section on 'Disorders of mineral metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When both calcium and phosphate levels are high (due in part to the increased intake of calcium [via calcium-based phosphate binders]), heterotopic deposition of hydroxyapatite in arteries, joints, soft tissues, and the viscera develops; when small arterioles are affected, tissue ischemia and calciphylaxis may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Tumoral collections of calcium phosphate crystals may also be a consequence of hyperphosphatemia and increased calcium levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased coronary arterial calcification is associated with coronary atherosclerosis, and is also related to the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consequences of elevated serum phosphorus, calcium, FGF-23 and parathyroid hormone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/18\">",
"     18",
"    </a>",
"    ]. If the oral phosphate binders described below are ineffective, parathyroidectomy may be required to control both the hyperparathyroidism and that part of the hyperphosphatemia that is due in part to PTH-induced release from bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remainder of this topic will review the recommended goals for serum phosphate at different levels of glomerular filtration rate and the issues that need to be considered in the treatment of hyperphosphatemia of chronic kidney disease. Many such patients are also treated with calcitriol or a vitamin D analog or calcimimetic in an attempt to suppress PTH release.",
"   </p>",
"   <p>",
"    However, calcitriol and other vitamin D analogs also increase intestinal phosphate absorption and can exacerbate the hyperphosphatemia unless bone remodeling is reduced due to inhibition of PTH secretion. High doses of vitamin D analogs also stimulate vascular calcification. Thus, such therapy should NOT be started until the serum phosphate concentration is under reasonable control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of the overall management of the patient with chronic kidney disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GUIDELINE TARGET LEVELS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     K/DOQI guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2003",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    practice guidelines made the following recommendations for goal serum phosphate at different levels of severity of chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At an estimated glomerular filtration rate between 15 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (stage 3 and 4 chronic kidney disease), the serum phosphate should be between 2.7 and 4.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.87 and 1.49",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      At an estimated glomerular filtration rate below 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (stage 5 chronic kidney disease), the serum phosphate should be between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 and 1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     KDIGO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 KDIGO practice guidelines were developed to provide recommendations for the evaluation and management of chronic kidney disease-mineral and bone disorder (CKD-MBD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/20\">",
"     20",
"    </a>",
"    ]. With respect to phosphate, the guidelines recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with stage 3 to 5 CKD not yet on dialysis, the serum phosphate should be maintained in the normal range. This recommendation was reiterated in the 2012 KDIGO guidelines on management of patients with CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among dialysis patients, the phosphate level should be lowered toward the normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GOAL SERUM PHOSPHATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the optimal levels are unclear, our target goals for phosphate levels have been chosen based upon attempts to prevent and manage the morbidity and mortality associated with hyperphosphatemia associated with CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with stage 3 to 5 CKD not yet on dialysis, we suggest maintaining serum phosphate levels in the normal range; these levels are consistent with the KDIGO guidelines.",
"     </li>",
"     <li>",
"      Among dialysis patients, we suggest maintaining serum phosphate levels between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 and 1.78",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      which is consistent with the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines. By comparison, the KDIGO guidelines only recommend lowering levels toward the normal range. We feel that this is not a practical goal since specific levels are not specified, and a phosphate level of 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is a reasonable inflection point at which increased mortality has been observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No randomized study has evaluated whether achieving these goal serum phosphate targets with phosphate lowering therapy has any bearing on clinically important outcomes. One randomized study compared the effect of phosphate binders on surrogate outcomes, including mineral metabolism and vascular calcification, among 148 patients with estimated GFR 20 to 45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/22\">",
"     22",
"    </a>",
"    ]. At 3, 6, and 9 months, compared with placebo, the use of phosphate binders (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    carbonate) was associated with a modest decrease in serum phosphorus (4.1 versus 3.9",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively), a large decrease in 24-hour urine phosphorus (22 percent decrease in the phosphate binder group), and a stable PTH value versus an increase in the placebo group.",
"   </p>",
"   <p>",
"    Surprisingly, among 81 patients for whom data were available, compared with placebo, the use of phosphate binders was associated with increases in calcification of the coronary arteries and abdominal aorta (18.1 versus 0.6 percent and 15.4 versus 3.4 percent, respectively). However, the inclusion of all phosphate binders together in the comparison to placebo and the small number of patients limits the interpretation of this observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies in dialysis patients and in non-dialysis CKD patients have examined whether the use of phosphate binders is associated with improved survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective observational study of incident dialysis patients followed for one year, the use of phosphate binders was significantly associated with a 25 percent lower one-year mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort of non-dialysis CKD patients in a single center study, a lower risk of mortality was noted with phosphate binder therapy (23 percent decrease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/25\">",
"       25",
"      </a>",
"      ]. However, this apparent benefit could stem from unequal periods of follow up; the median period of follow up was approximately four years for patients not given phosphate binders compared to just two years for patients treated with phosphate binders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a retrospective cohort study of 7076 patients dialyzed in the United Kingdom from 2002 to 2004 suggested that patients who attained the 2003 KDOQI targets for phosphate (3.5 to 5.5",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    calcium (8.4 to 9.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and PTH (150 to 300",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    did not have better survival compared to those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/26\">",
"     26",
"    </a>",
"    ]. This study did not include any information about the use of medication, vitamin D and alkaline phosphatase levels or dialysate calcium concentration.",
"   </p>",
"   <p>",
"    Randomized trials are needed to determine whether phosphate lowering in CKD impacts important clinical endpoints.",
"   </p>",
"   <p>",
"    A significant amount of epidemiologic and observational evidence suggests that higher than normal phosphate levels, including those in the upper levels of the normal range, may increase the risk of cardiovascular disease and death in patients with normal kidney function as well as those with CKD stages 3 to 5 not yet on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/15,27-29\">",
"     15,27-29",
"    </a>",
"    ]. With respect to patients with chronic kidney disease who are not yet dialysis dependent, this was perhaps best shown in a study of 3490 patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/15\">",
"     15",
"    </a>",
"    ]. At a median follow-up of two years, an increased mortality risk was observed in those with serum phosphate levels greater than 3.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.81",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The mortality risk also increased as serum phosphate levels increased, with each 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    positive increment being associated with a 23 percent enhanced risk of death.",
"   </p>",
"   <p>",
"    A sustained elevation in serum phosphate alone is also associated with increased mortality among patients with end-stage renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/14,30-35\">",
"     14,30-35",
"    </a>",
"    ]. This was best shown in a meta-analysis of 12 studies that included 92,345 patients with CKD, over 97 percent of whom were on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/35\">",
"     35",
"    </a>",
"    ]. The overall mortality risk increased 18 percent for every 1",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    increase in the serum phosphorus (RR 1.18, 95% CI 1.12-1.25).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two principal modalities are used in an attempt to prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reverse the hyperphosphatemia of renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/20,36\">",
"     20,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restricting dietary phosphate intake",
"     </li>",
"     <li>",
"      The administration of different agents, named phosphate binders, to bind ingested phosphate in the gut",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phosphate restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a moderate restriction of phosphate intake in patients with CKD, providing this can be done without compromising nutritional status; approximately 900 mg per day is a level that at least some patients will find acceptable. Phosphate restriction should primarily include processed foods and colas and NOT high biologic value foods such as meat and eggs.",
"   </p>",
"   <p>",
"    However, different considerations are present in maintenance dialysis. A large fraction of dialyzed patients have either overt or borderline malnutrition. Thus, protein supplementation rather than protein restriction is the goal. In this setting, the patient should be encouraged to avoid unnecessary dietary phosphate (as in phosphorus-containing food additives, dairy products, certain vegetables, many processed foods, and colas) while increasing the intake of high biologic value sources of protein (such as meat and eggs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Food additives are an under-appreciated source of dietary phosphorus and patient instruction to read food labels and avoid these is very important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the phosphate content of a food, measures aimed at lowering phosphate levels also depend upon an understanding of the ability to absorb phosphorus within the gastrointestinal tract. Thus, phosphorus contained in highly processed food is easily absorbed; by comparison, plant-derived phosphorus is less easily absorbed because it is in the form of phytate phosphorus, and the human intestine does not secrete phytase, the enzyme required for absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data examining the efficacy of dietary phosphate restrictions on patient important outcomes. In one randomized study that evaluated the effect of dietary restriction on vascular calcification, a low phosphate diet alone failed to prevent progression of such calcification among patients with CKD not yet on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/39\">",
"     39",
"    </a>",
"    ]. In a post hoc analysis of data from the HEMO study, prescribed phosphate restriction was not associated with improved survival of hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/40\">",
"     40",
"    </a>",
"    ]. In fact, there was a stepwise trend toward better survival with less restrictive prescribed phosphate intake in this study. Major findings from the HEMO study are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link&amp;anchor=H11#H11\">",
"     \"Kt/V and the adequacy of hemodialysis\", section on 'HEMO study'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few small studies have found that phosphate restriction does not compromise nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], although in the HEMO study cohort, phosphate restriction tended to be associated with poorer nutritional indices on baseline analysis and a persistently greater need for nutritional supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are consistent with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Phosphate binders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Overview and choice of binder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with CKD not yet on dialysis and nearly all dialyzed patients (undergoing conventional dialysis) require administration of oral phosphate binders to control serum phosphate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19,20,44,45\">",
"     19,20,44,45",
"    </a>",
"    ]. Thus, among patients with CKD and hyperphosphatemia, we suggest the administration of phosphate binders.",
"   </p>",
"   <p>",
"    At present, the major modalities to lower phosphate levels are the administration of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium-containing phosphate binders.",
"     </li>",
"     <li>",
"      Non-calcium containing phosphate binders. The two principal options are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      and lanthanum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As shown in a systematic review, these phosphate binders are all effective in lowering phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no conclusive evidence suggesting that the use of one agent rather than another provides significant clinical benefits related to mortality or bone fractures among dialysis patients. Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    may decrease mortality among CKD patients who are not on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sevelamer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A strategy that relies principally upon calcium-containing phosphate binders increases the risk of positive calcium balance, particularly in the setting of concomitant vitamin D therapy. Compared with the use of non-calcium-containing phosphate binders, this may increase the risk of vascular calcification and arterial disease and is associated with decreased serum PTH levels and increased serum calcium levels.",
"   </p>",
"   <p>",
"    We therefore favor an overall strategy that limits the intake of calcium. This is consistent with both the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO guidelines. We keep daily elemental calcium intake from binders to less than 1500 mg, and total elemental calcium from diet and binders to less than 2000 mg in patients on concurrent therapy with active vitamin D analogues. Higher doses of calcium may be tolerated in patients not receiving vitamin D analogues or who have hypocalcemia while being treated with calcimimetics.",
"   </p>",
"   <p>",
"    The choice between the two types of binders varies based upon a range of factors. These include the presence of vascular calcification, levels of calcium and PTH, administration of other agents to help control secondary hyperparathyroidism, adverse effects, and others. Among hyperphosphatemic patients, for example, the dose of calcium-containing phosphate binders should be restricted in the setting of hypercalcemia, arterial calcification, adynamic bone disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistently low parathyroid hormone (PTH) levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Calcium salts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is an overview of the use of calcium salts as phosphate binders. The specific evidence in terms of clinically relevant outcomes with calcium-containing phosphate binders versus other agents is discussed in sections below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sevelamer'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Lanthanum'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For many years,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    was the phosphate binder of choice. This regimen, however, created a new problem, aluminum intoxication due to the gradual tissue accumulation of absorbed aluminum. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Other phosphate binders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The problems with aluminum led to the preferential administration of calcium salts to bind intestinal phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1,2,47\">",
"     1,2,47",
"    </a>",
"    ]. Initial studies with calcium salts revealed that adequate control of the hyperphosphatemia was achieved in approximately 70 percent of patients treated with calcium salts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/47\">",
"     47",
"    </a>",
"    ]; the remaining patients required the addition of some aluminum-containing antacid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients are administered the calcium-containing phosphate binders,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1,47,48\">",
"     1,47,48",
"    </a>",
"    ]. Calcium acetate may be a more efficient phosphate binder than calcium carbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The latter dissolves only at an acid pH and many patients with advanced renal failure have achlorhydria or are taking H2-blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/48\">",
"     48",
"    </a>",
"    ]. Calcium acetate, on the other hand, is soluble in both acid and alkaline environments. The net effect is that only one-half as much calcium is required with calcium acetate. However, this difference does not appear to be clinically important, since the incidence of hypercalcemia is similar to that seen with higher doses of calcium carbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1,50,51\">",
"     1,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy of elevated phosphate levels that is refractory to diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dialysis can therefore be initiated with calcium-based phosphate binders. The dose of calcium-containing phosphate binders is generally increased until the serum phosphate falls to normal values for patients with stage 3 to 5 CKD not yet on dialysis or between 4.5 and 5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.5 and 1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for dialysis patients or hypercalcemia ensues. There is no known harm in maintaining plasma calcium levels at the lower end of the normal range (8.4 to 9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.1 to 2.35",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    especially in patients treated with calcimimetics. However, a serum calcium in the upper limit of a normal population may be acceptable in patients treated with active vitamin D analogues, provided that serum phosphate is &lt;5.5",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    One potential complication of calcium therapy is that absorption of some of the administered calcium may promote the development of coronary arterial calcification, which is postulated to be associated with coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. To help decrease this possibility, we suggest that the total dose of elemental calcium (including dietary sources) should not exceed 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"     19",
"    </a>",
"    ], and the amount of elemental calcium should be no more than 1.5 grams per day. Even these doses of calcium result in positive calcium balance in the setting of vitamin D therapy, which may have untoward long-term consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phosphate binders are most effective if taken with meals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/56\">",
"     56",
"    </a>",
"    ]. This regimen has the advantages of binding dietary phosphate and therefore of leaving less free calcium available for absorption. In comparison, administration between meals only binds the phosphate present in intestinal secretions and results in a greater degree of calcium absorption. Although not generally desirable, the combination of more calcium absorption and less phosphate binding may be preferred in patients who remain hypocalcemic despite a normal or low plasma phosphate concentration.",
"   </p>",
"   <p>",
"    Although generally well tolerated, hypercalcemia is a common complication of this regimen; as previously mentioned, this problem is most likely to occur if a vitamin D preparation is also given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/57\">",
"     57",
"    </a>",
"    ] or if patient has decreased bone turnover due to osteomalacia or adynamic bone disease, thereby limiting uptake of the extra calcium by bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1,58\">",
"     1,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Adynamic bone disease'",
"    </a>",
"    .) To limit calcium loading, it is also reasonable to restrict the dose of calcium-based phosphate binders in patients with evidence of vascular calcification. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We therefore recommend that calcium-based phosphate binders not be used in patients with hyperphosphatemia who are also hypercalcemic. In addition, we also suggest that the dose of calcium-based phosphate binders be limited in patients with suspected adynamic bone disease, vascular calcification, and persistently low plasma PTH levels. Adynamic bone disease can be suspected in patients with a low plasma PTH level who develop hypercalcemia on calcium based phosphate binders or active vitamin D therapy. A bone biopsy is the only way to definitively diagnose this disorder.",
"   </p>",
"   <p>",
"    Thus, careful monitoring of the serum calcium concentration is essential with the chronic administration of calcium salts, particularly in patients on hemodialysis where the dialysate calcium concentration can vary and therefore impact the ability to administer calcium-containing phosphate binders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To help reduce calcium loads, the 2003",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines suggested that the dialysate calcium concentration in hemodialysis or peritoneal dialysis should be 2.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (1.25",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"       19",
"      </a>",
"      ]. The 2009 KDIGO guidelines suggest that the dialysate calcium concentration in hemodialysis or peritoneal dialysis should be between 2.5 and 3.0",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      We suggest using a dialysate calcium concentration of 2.5",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      a concentration in which there is no net calcium flux in most patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By comparison, a dialysate calcium concentration between 3 and 3.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (1.50 to 1.75",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is much higher than that in the plasma, resulting in a positive calcium balance and increasing the risk of hypercalcemia in patients also taking calcium supplements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/59\">",
"       59",
"      </a>",
"      ]. It is estimated that, during a four-hour dialysis session, patients gain almost 900 mg of calcium when dialyzed against a 3.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      dialysate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients treated with continuous ambulatory peritoneal dialysis (CAPD), a low calcium bath (2.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    has also been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/60\">",
"     60",
"    </a>",
"    ]. However, extended treatment with low calcium peritoneal dialysate fluids may be associated with an increased risk of severe hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Serum PTH levels and bone metabolism must be closely monitored if low calcium peritoneal dialysate fluids are utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sevelamer",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     Sevelamer",
"    </a>",
"    hydrochloride (Renagel) and the newer sevelamer carbonate (Renvela) are nonabsorbable agents that contain neither calcium nor aluminum. These drugs are cationic polymers that bind phosphate through ion exchange. Since sevelamer carbonate does not lower serum bicarbonate, it is likely that it will become the preferred binder in this class (see below).",
"   </p>",
"   <p>",
"    As noted with other phosphate binding agents, a significant number of trials have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    is effective in lowering serum phosphate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/64-73\">",
"     64-73",
"    </a>",
"    ]. Although conventional dosing of sevelamer is effective, compliance with the requirement for thrice daily dosing with any phosphate binder can be problematic. A small crossover study found that thrice daily and once daily dosing were equally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/72\">",
"     72",
"    </a>",
"    ]. Although further study is required, once daily dosing may simplify the dosing regimen, thereby resulting in increased compliance and overall efficacy.",
"   </p>",
"   <p>",
"    The important issues with respect to the choice of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    versus other agents are their relative effects on mortality, vascular calcification, bone disease, and biochemical effects, particularly hypercalcemia. The following sections will address some of the evidence evaluating the relative effects of sevelamer on mortality, vascular calcification, and biochemical indices.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality &mdash; Calcium- and non-calcium-based phosphate binders appear to have similar effects on all-cause or cardiovascular mortality in hemodialysis patients. A small number of randomized trials and a meta-analysis have evaluated mortality with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      versus calcium-based phosphate binders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/69,70,74-79\">",
"       69,70,74-79",
"      </a>",
"      ]. The following is a brief review of the largest studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A meta-analysis of five trials consisting of 2429 patients (2103 from the DCOR study, next paragraph) reported a similar risk difference for all-cause mortality between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      and calcium-based phosphate binders (-2 percent, 95% CI -6 to +2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The three-year Dialysis Clinical Outcomes Revisited (DCOR) trial evaluated mortality and morbidity outcomes among 2103 prevalent hemodialysis patients randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or calcium-based phosphate binders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/76\">",
"       76",
"      </a>",
"      ]. At up to 45 months, there was no significant difference in all-cause mortality (RR 0.93, 95% CI 0.79-1.11) and cardiovascular mortality (RR 0.93, 95% CI 0.74-1.17). A secondary analysis reported no differences in mortality, but there were benefits with sevelamer on all cause hospitalizations and hospital days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the prospective randomized RIND trial, there was relatively less progression of coronary artery calcification in 109 incident hemodialysis patients randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      versus calcium-based phosphate binders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/74\">",
"       74",
"      </a>",
"      ]. In a post-hoc analysis of this study, mortality at a median follow-up of 44 months was (borderline) significantly lower with sevelamer",
"      <span class=\"nowrap\">",
"       (5.3/100",
"      </span>",
"      patient-years versus",
"      <span class=\"nowrap\">",
"       10.6/100",
"      </span>",
"      patient-years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/75\">",
"       75",
"      </a>",
"      ]. With multivariate analysis, there was a greater risk for death with calcium-based phosphate binders (hazard ratio 3.1, CI 1.23-7.61). In addition, the baseline coronary artery calcium level was a significant predictor of mortality.",
"      <br/>",
"      <br/>",
"      Among CKD patients who are not on dialysis, one limited study has suggested that sevelamer compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      may decrease mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/46\">",
"       46",
"      </a>",
"      ]. In a randomized nonblinded study that included 212 patients, fewer deaths were associated with sevelamer compared with calcium carbonate at 36 months (12 versus 22). The composite endpoint of death or initiation of dialysis was lower among patients on sevelamer compared with calcium carbonate (43 versus 64, respectively).",
"      <br/>",
"      <br/>",
"      The decreased mortality associated with sevelamer may have been related in part to its greater efficacy in reducing serum phosphorus and decreased risk of hypercalcemia compared with calcium carbonate; although the proportion of patients who achieved the targeted phosphorus concentration (2.7 to 4.6",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      for patients with stage 4 CKD and 3.5 to 5.5",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      for those with stage 5 CKD), the average phosphorus concentration was lower among patients treated with sevelamer compared with calcium carbonate (4.37 versus 4.85",
"      <span class=\"nowrap\">",
"       mg/dl,",
"      </span>",
"      respectively). The average calcium concentrations and the incidence of hypercalcemia were lower in the sevelamer compared with calcium carbonate group (8.6 versus 9.4",
"      <span class=\"nowrap\">",
"       mg/dl,",
"      </span>",
"      and 5 versus 78 percent, respectively). The apparent survival benefit may also have been related to decreases in C-reactive protein, total cholesterol and LDL cholesterol, also observed with greater frequency in association with sevelamer.",
"      <br/>",
"      <br/>",
"      Although larger randomized studies are required to confirm these data, sevelamer is a good option for CKD patients who are not on dialysis and who require a phosphate binder. However, calcium-containing binders would be an acceptable therapy in many non-dialysis CKD patients, particularly if cost is an issue, providing such patients are not hypercalcemic.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effect on calcification &mdash; Although the data are not consistent, there appears to be relatively less progression of vascular calcification with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      versus calcium-containing phosphate binders among patients with CKD. However, it is unclear whether this benefit is associated with improvements in morbidity and mortality from cardiovascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The prospective and randomized \"Treat-to-Goal\" and RIND trials both reported relatively less progression of coronary artery calcification with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      versus calcium-containing phosphate binders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/69,74,75,80\">",
"       69,74,75,80",
"      </a>",
"      ]. By comparison, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/48/39685?source=see_link\">",
"       Calcium Acetate",
"      </a>",
"      Renagel Evaluation (CARE)-2 trial found similar progression of coronary artery calcification with sevelamer and calcium acetate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The differences observed between the \"Treat-to-Goal\", RIND, and the CARE-2 trial may be due, in part, to study limitations and the inclusion of a higher proportion of diabetic patients in the CARE-2 trial. This last finding may have resulted in a substantially greater progression of calcification.",
"     </li>",
"     <li>",
"      In the randomized study cited above, de novo coronary artery calcification detected by multi-slice computed tomography was lower at 36 months among patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      (13 versus 82 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Given these findings, calcium-containing phosphate binders remain a cost-effective first-line treatment option for the control of hyperphosphatemia, although the risk of long-term calcium exposure remains a concern. Limiting calcium-containing phosphate binder use and the early use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      in patients with persistent hyperphosphatemia, even in combination with calcium-containing binders, may be most appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone histology &mdash; There appears to be no major difference between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      and calcium-based phosphate binders in terms of bone histology. A few randomized prospective studies have been performed that found varying outcomes in different patients, with a consistent finding of improved bone volume with calcium therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/82-84\">",
"       82-84",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although the evidence is somewhat inconsistent, there appears to be a correlation between increased calcium intake and an increased incidence of both adynamic bone disease and vascular calcification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/82,85,86\">",
"       82,85,86",
"      </a>",
"      ]. The increased calcium intake was most commonly the result of the use of calcium-containing phosphate binders compared with either sevelamer or lanthanum. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Lanthanum'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Calcium and PTH levels &mdash; A number of randomized prospective studies have found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      compared with calcium-based phosphate binders is associated with lower serum calcium levels and higher phosphate and PTH levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/69,74,75,80,81,87\">",
"       69,74,75,80,81,87",
"      </a>",
"      ]. In the prospective \"Treat-to-Goal\" trial, 200 patients undergoing maintenance hemodialysis were randomly assigned to sevelamer or calcium-based phosphate binders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/69\">",
"       69",
"      </a>",
"      ]. At one year, although serum phosphate control was similar with both agents (5.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.65",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      sevelamer was associated with the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lower incidence of hypercalcemia (5 versus 16 percent)",
"     </li>",
"     <li>",
"      A minimal decrease in the serum calcium concentration (9.5 versus 9.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.35 and 2.43",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Decreased incidence of low PTH levels (30 versus 57 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic acidosis &mdash; One problem associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      hydrochloride is the possible induction of metabolic acidosis. As a result, a buffered form of sevelamer, sevelamer carbonate (Renvela), has been developed. It is associated with higher serum bicarbonate levels than Renagel, but these agents appear to be equivalent in their ability to control phosphate levels. This was shown in a double-blind randomized trial of 79 hemodialysis patients in which patients were administered eight weeks of sevelamer carbonate or sevelamer hydrochloride and then crossed-over to the other agent for an additional eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/88\">",
"       88",
"      </a>",
"      ]. Both agents similarly controlled mean serum phosphate levels, while bicarbonate levels were significantly higher with sevelamer carbonate (+1.3",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      The induction of metabolic acidosis with sevelamer hydrochloride is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Economic impact &mdash; There is a large difference in cost between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      and calcium based phosphate binders, with sevelamer being much more expensive. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      To address the possible economic impact of the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines, one 2004 study performed a systematic review of the use of this agent in the over 50 percent of Canadian and United States dialysis patients who would fulfill",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      criteria for its administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/89\">",
"       89",
"      </a>",
"      ]. It was estimated that, in the United States, approximately 780 million dollars would be required per year for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      alone to meet these recommendations.",
"     </li>",
"     <li>",
"      An economic evaluation of the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      for all dialysis patients found that the cost per quality-adjusted life year was economically unattractive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/90\">",
"       90",
"      </a>",
"      ]. This was particularly true given that sevelamer was associated with uncertain clinical benefits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Lanthanum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lanthanum, a rare earth element, has significant phosphate binding properties. This agent has been shown to be effective in multiple studies that have assessed the effectiveness in lowering phosphate levels of different dosing regimens among dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/91-98\">",
"     91-98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of a high daily cost when compared to calcium-based binders,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    is generally restricted to the same population of dialysis patients that now receives",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    . This principally involves patients with hypercalcemia, or as an adjunct to a regimen supplying a maximum dose of 1500 mg of elemental calcium from calcium-based phosphate binders. A relative advantage with lanthanum, compared with other phosphate binders, may be a reduced daily tablet burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with calcium-containing phosphate binders and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    , the relative effects of lanthanum on mortality and vascular calcification have not been evaluated. The principal evaluated outcomes have been the relative effects on bone and biochemical parameters.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone histology &mdash; The relative effects on bone histology with lanthanum compared with calcium-containing phosphate binders have been evaluated in several randomized prospective studies. In general, there were no consistent benefits or adverse effects observed with lanthanum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/85,100-102\">",
"       85,100-102",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, compared with the use of lanthanum, there appears to be a correlation between increased calcium intake via calcium-containing phosphate binders and a relatively increased incidence of both adynamic bone disease and vascular calcification.",
"     </li>",
"     <li>",
"      Biochemical parameters and adverse effects &mdash; As observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      , lanthanum appears to be associated with a lower incidence of hypercalcemia and decreased PTH levels versus calcium-containing phosphate binders. This has been shown in multiple randomized prospective studies that have evaluated the effectiveness of lanthanum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/91-93,95,97,98,100,101,103\">",
"       91-93,95,97,98,100,101,103",
"      </a>",
"      ]. In a multicenter European trial, 800 dialysis patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"       lanthanum carbonate",
"      </a>",
"      (Fosrenol, 750 to 3,000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      (1,500 to 9,000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      with the dose titrated to achieve serum phosphate levels of less than 5.58",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.80",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/95\">",
"       95",
"      </a>",
"      ]. At six months, adequate phosphate control was achieved in approximately 65 percent of both groups. However, hypercalcemia was significantly more common with calcium carbonate (20.2 versus 0.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among dialysis patients, no significant clinical adverse effects have yet been reported with lanthanum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/91-93,95,97,98,100,101,103\">",
"     91-93,95,97,98,100,101,103",
"    </a>",
"    ]. This was best studied in a report in which the long-term safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"     lanthanum carbonate",
"    </a>",
"    administered for up to two years was evaluated in 1359 hemodialysis patients randomly assigned to lanthanum (maximum dose of 3,000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or their pre-study phosphate binder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/97\">",
"     97",
"    </a>",
"    ]. Average exposure to standard therapy was higher than that with lanthanum (401 and 370 days, respectively). The incidence of adverse effects was similar in both groups, which principally consisted of gastrointestinal effects. No evidence of hepatic toxicity was observed. Control of phosphorus was similar in both arms, although serum calcium levels were lower with lanthanum.",
"   </p>",
"   <p>",
"    However, the long-term safety of lanthanum, particularly its possible effect on bone and other organs, remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. In a short-term animal model, for example, there was progressive accumulation of lanthanum in several organs of animals fed lanthanum for up to 110 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/106\">",
"     106",
"    </a>",
"    ]. This was observed particularly in the liver, in which there were nearly 100 fold higher levels measured in uremic rats fed lanthanum versus uremic rats fed a control diet. Lanthanum shares biochemical properties with gadolinium, an agent associated with the development of nephrogenic systemic fibrosis in patients with severe renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/107\">",
"     107",
"    </a>",
"    ]. However, an association with this disorder and lanthanum has not been reported.",
"   </p>",
"   <p>",
"    Long term clinical studies are currently ongoing. Preliminary evidence suggests the absence of hepatotoxicity with exposure of up to four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practically all studies have evaluated the efficacy and safety of lanthanum in dialysis patients. Among individuals with stage 3 and 4 chronic kidney disease, a phase 2 placebo-controlled study found that lanthanum reduced phosphate levels and was well tolerated over an eight-week period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/108\">",
"     108",
"    </a>",
"    ]. Long-term studies are required to better assess the efficacy and tolerability of this agent.",
"   </p>",
"   <p>",
"    Until more studies and experiences with each agent are available, cost and patient tolerability are the only factors that can be used to determine whether to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    or lanthanum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other phosphate binders",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     Aluminum hydroxide",
"    </a>",
"    was, for many years, the phosphate binder of choice, forming insoluble and nonabsorbable aluminum phosphate precipitates in the intestinal lumen. This regimen, however, created a new problem, aluminum intoxication due to the gradual tissue accumulation of absorbed aluminum.",
"   </p>",
"   <p>",
"    The major manifestations of this problem develop in the bone, skeletal muscle, and the CNS, leading to vitamin D-resistant osteomalacia, a refractory, microcytic anemia, bone and muscle pain, and a dementia. There appears to be no safe dose of aluminum in chronic kidney disease that is also large enough to control the serum phosphate concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnesium-containing antacids (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    ) have also generally been avoided in patients with kidney dysfunction. This is because of the risk of hypermagnesemia and the frequent development of diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Increased and/or extended hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard dialysis is limited in its ability to remove phosphate. Although dialysis membranes are relatively efficient, there is only a slow efflux of phosphate from the large intracellular stores into the extracellular fluid, which is undergoing dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, lengthening dialysis (within standard dialysis regimens) or using larger, high efficiency dialyzers is unlikely to substantially increase phosphate removal. The average standard dialysis removes approximately 900 mg of phosphate.",
"   </p>",
"   <p>",
"    By comparison, extremely long",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent dialysis clears a larger amount of phosphate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=see_link&amp;anchor=H9482545#H9482545\">",
"     \"Short daily hemodialysis\", section on 'Frequent Hemodialysis Network (FHN) daily trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients, control of serum phosphate can be achieved without the use of any phosphate binders. For patients with refractory hyperphosphatemia and who are willing to accept this form of dialysis, this form of dialysis may be the best approach. This is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     APPROACH TO HYPERPHOSPHATEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;To optimally manage elevated phosphate levels in patients with CKD, it is important to first assess the presence or absence of other mineral abnormalities, vascular calcifications, and note the administration of concurrent therapies. We therefore obtain phosphate, calcium, and PTH levels initially and then on an ongoing basis, particularly after changes in therapeutic measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients, we aim to maintain serum phosphate levels between 3.5 and 5.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.13 and 1.78",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Our initial step is to restrict dietary phosphate to 900 mg per day.",
"   </p>",
"   <p>",
"    Among dialysis patients with elevated phosphate levels that are refractory to maintenance dialysis therapy and diet, we recommend the administration of phosphate-binding agents. Our specific approach varies based upon the serum calcium level:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with calcium &gt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend the administration of a non-calcium containing phosphate binder rather than calcium containing binders. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or lanthanum can be given.",
"     </li>",
"     <li>",
"      Among patients with calcium levels between 8.4 and 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10 and 2.37",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      management varies based upon the presence of adynamic bone disease, low PTH levels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular calcification:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among those without such comorbidities, we suggest first titrating a calcium-based phosphate binder (up to 1500 mg of elemental calcium from binders alone). Higher doses of calcium may be tolerated in patients not receive vitamin D analogues or who have hypocalcemia while being treated with calcimimetics. If phosphate remains above 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      despite this strategy, we then add a non-calcium containing phosphate binder. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or lanthanum can be given.",
"     </li>",
"     <li>",
"      Among those with adynamic bone disease, low PTH levels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular calcification, a non-calcium based phosphate binder is preferred rather than a calcium-containing phosphate binder. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"       lanthanum carbonate",
"      </a>",
"      can be given in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with calcium levels &lt;8.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend a calcium-based phosphate binder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients do not achieve the recommended serum phosphate goals with the above regimen due in part to the use of various agents to help control PTH levels. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Goal serum phosphate'",
"    </a>",
"    above.)&nbsp;Vitamin D analogs may contribute, raising both phosphate and calcium concentrations. A possible alternative is the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , which acts by a different mechanism and produces significant reductions in PTH, calcium, and phosphate levels. The data supporting these conclusions and our approach to such patients are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More frequent and more intensive dialysis can also lower phosphate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"     19",
"    </a>",
"    ]. Extremely long",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent dialysis, such as that provided by nocturnal hemodialysis, clears a large amount of phosphate. Among patients with refractory hyperphosphatemia, nocturnal hemodialysis is an option among those who are willing to accept this form of dialysis. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Increased and/or extended hemodialysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    except for short-term therapy (four weeks for one course only) of severe hyperphosphatemia. Many such patients are candidates for parathyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Stage 3 to 5 CKD not yet on dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our initial step in the management of hyperphosphatemia in patients with stage 3 to 5 CKD not yet on dialysis is the restriction of dietary phosphate to 900",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Among",
"    patients with serum phosphate levels greater than target levels despite dietary phosphorus restriction after one month, we suggest the administration of phosphate binders. The two principal options for phosphate binder therapy are calcium and non-calcium based phosphate binders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with calcium &gt;9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;2.37",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend the administration of a non-calcium containing phosphate binder rather than calcium containing binders. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or lanthanum can be given. Since hypercalcemia is unusual in CKD stage 3 to 5, evaluation for secondary non-PTH mediated causes should be undertaken if PTH values are not significantly elevated and patients are not receiving active vitamin D therapy.",
"      <br/>",
"      <br/>",
"      Primary hyperparathyroidism can occur in this setting, but distinguishing this disorder from secondary hyperparathyroidism can be difficult. Primary hyperparathyroidism might be suspected in hypercalcemic patients with stage 3 to 4 CKD and a low serum phosphate level in the absence of phosphate binders.",
"     </li>",
"     <li>",
"      Among patients with calcium levels between 8.4 and 9.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10 and 2.37",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      management varies based upon the presence of adynamic bone disease, low PTH levels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular calcification:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among those without such comorbidities, we suggest a calcium-based phosphate binder. The dose of calcium-containing phosphate binders is generally increased until the serum phosphate falls to normal values or hypercalcemia ensues. The safe dose of calcium is not known in stage 3 and 4 CKD but likely exceeds the 1500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      limit in end stage renal disease patients suggested by the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      work group.",
"     </li>",
"     <li>",
"      Among those with adynamic bone disease, low PTH levels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular calcification, we suggest a non-calcium based phosphate binder rather than a calcium-containing phosphate binder. Either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"       sevelamer",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/37/28244?source=see_link\">",
"       lanthanum carbonate",
"      </a>",
"      can be given in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with calcium levels &lt;8.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.10",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we recommend a calcium-based phosphate binder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among all patients with CKD, we avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    except for short-term therapy (four weeks for one course only) of severe hyperphosphatemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Approach to hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of hypercalcemia (calcium &gt;10.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    corrected for serum albumin) and persistent hyperphosphatemia may be a particular problem with calcium therapy and active vitamin D analog administration, possibly leading to extraskeletal calcium phosphate deposition. In this setting, we suggest that the dose of calcium-based phosphate binders should be decreased or therapy discontinued,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapy should be switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    to control phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, the dose of active vitamin D sterols should be lowered or therapy should be discontinued until calcium levels return to 8.4 to 9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.10 to 2.37",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     NOVEL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given",
"    that the current approach to management of hyperphosphatemia is not optimal, a number of alternative therapies are undergoing evaluation. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    and polynuclear iron (III)-oxyhydroxide phosphate (PA21).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998753883\">",
"    <span class=\"h2\">",
"     Nicotinamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/27/38322?source=see_link\">",
"     Nicotinamide",
"    </a>",
"    , a metabolite of nicotinic acid (niacin, vitamin B3), inhibits the",
"    <span class=\"nowrap\">",
"     Na/Pi",
"    </span>",
"    co-transport system in the gastrointestinal tract and kidneys and may be effective in lowering phosphate levels in dialysis patients by reducing gastrointestinal tract phosphate absorption:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study of 20 dialysis patients, Niaspan (prolonged-release nicotinic acid) was administered in slowly increasing doses, with 17 patients eventually tolerating &gt;1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/109\">",
"       109",
"      </a>",
"      ]. Among such patients, treatment for 12 weeks significantly lowered serum phosphate values (7.2 to 5.9",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and increased serum HDL cholesterol levels.",
"     </li>",
"     <li>",
"      A randomized placebo-controlled cross-over trial of 33 patients found that niacinamide (titrated from 500 to 1500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      significantly lowered phosphate levels (6.26 to 5.47",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/110\">",
"       110",
"      </a>",
"      ]. Adverse effects were similar with both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998753979\">",
"    <span class=\"h2\">",
"     Polynuclear iron (III)-oxyhydroxide phosphate (PA21)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various dosages of polynuclear iron (III)-oxyhydroxide phosphate (PA21) were compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    in a randomized, multicenter open label study that included 154 hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/111\">",
"     111",
"    </a>",
"    ]. At six weeks, PA21 at dosages of 5.0, 7.5, 10.0 and 12.5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    but not 1.25",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    decreased the serum phosphorus. Dosages of 5.0 and 7.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    produced similar decreases in serum phosphorus to sevelamer dosed at 4.8",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    There was no difference between PA21 and sevelamer in the rate of adverse events (61 versus 58 percent, respectively). The most common adverse event associated with PA21 was hypophosphatemia (18 percent).",
"   </p>",
"   <p>",
"    Further study is required to better understand the efficacy and safety of these and related agents in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CITRATE AND ALUMINUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38628?source=see_link\">",
"     Calcium citrate",
"    </a>",
"    has also been used as a phosphate binder. This preparation, however, should be AVOIDED in patients with renal failure, since citrate can markedly increase intestinal aluminum absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/112,113\">",
"     112,113",
"    </a>",
"    ] and possibly induce aluminum neurotoxicity or the rapid onset of symptomatic osteomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrate appears to enhance aluminum absorption both by keeping aluminum soluble (via the formation of aluminum citrate) in the intestinal lumen and by complexing with luminal calcium; the ensuing decrease in free calcium then leads to increased permeability of the tight junctions between the cells, a change that can markedly enhance passive aluminum absorption (",
"    <a class=\"graphic graphic_figure graphicRef55777 \" href=\"mobipreview.htm?12/8/12429\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In comparison, acetate does not enhance aluminum absorption and therefore can be safely given, even with the concurrent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar considerations apply to the administration of aluminum-containing antacids with sodium citrate (Bicitra&trade;), which has been used to treat uremic acidosis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    is preferred in advanced kidney disease even if the patient is not being treated with aluminum, since many foods and medications contain some aluminum (such as buffered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/112\">",
"     112",
"    </a>",
"    ]. However, if such items are assiduously avoided, sodium citrate can be used in some patients unable to tolerate sodium bicarbonate, since it does not produce the bloating associated with bicarbonate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/57/33690/abstract/115\">",
"     115",
"    </a>",
"    ]. These considerations related to aluminum are also likely to apply to the novel phosphate binder, ferric citrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tendency toward phosphate retention begins early in renal disease. However, phosphate balance and a normal serum phosphate concentration are generally maintained (at the price of elevated PTH and FGF23 levels) until the glomerular filtration rate (GFR) falls below 25 to 40",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      At this relatively late stage, dietary phosphate restriction may still minimize positive phosphate balance and may reduce the serum concentration of both phosphate and PTH, although not usually to normal. As a result, oral phosphate binders are frequently required. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      and KDIGO have published guidelines concerning the management of hyperphosphatemia in patients with chronic kidney disease (CKD). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Guideline target levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restricting dietary phosphate intake and the administration of phosphate binders are the two principal modalities used to reverse the hyperphosphatemia of CKD. To optimally manage elevated phosphate levels in all patients with CKD, it is important to first assess the presence or absence of other mineral abnormalities, vascular calcifications, and note the administration of concurrent therapies, particularly vitamin D and vitamin D analogs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest maintaining serum phosphate levels between 3.5 and 5.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.13 and 1.78",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      among dialysis patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Goal serum phosphate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among dialysis patients with phosphate levels above target levels, we first suggest restricting dietary phosphate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our initial step is to restrict dietary phosphate to 900 mg per day. The patient should be encouraged to avoid unnecessary dietary phosphate (as in phosphorus-containing food additives, dairy products, certain vegetables, many processed foods, and colas) while maintaining the intake of high biologic value sources of protein.",
"      <br/>",
"      <br/>",
"      Among dialysis patients with elevated phosphate levels that are refractory to maintenance dialysis therapy and diet, we suggest the administration of phosphate-binding agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Our approach varies based upon calcium levels and the presence of comorbid conditions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Dialysis patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite dietary restriction, optimal doses of phosphate binders, and conventional dialysis, some dialysis patients do not achieve the recommended serum phosphate goals. This may be due in part to the use of various agents to help control parathyroid hormone levels, particularly vitamin D analogs, and well as other issues. The approach in these patients is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"       \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Dialysis patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among dialysis patients with persistent hyperphosphatemia, we suggest increasing phosphate removal via hemodialysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Among patients with refractory hyperphosphatemia, nocturnal hemodialysis is an option among those who are willing to accept this form of dialysis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Increased and/or extended hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among all patients with CKD, we recommend NOT administering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      except for short-term therapy (four weeks for one course only) of severe hyperphosphatemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other phosphate binders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stage 3 to 5 CKD not yet on dialysis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest maintaining serum phosphate levels in the normal range among patients with stage 3 to CKD not yet on dialysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among patients with stage 3 to 5 CKD not yet on dialysis with hyperphosphatemia, we first suggest restricting dietary phosphate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our initial step is to restrict dietary phosphate to 900 mg per day. Among patients with serum phosphate levels greater than target levels despite dietary phosphorus restriction after 4 weeks, we suggest the administration of phosphate binders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our specific approach varies based upon calcium levels and the presence of comorbid conditions. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Stage 3 to 5 CKD not yet on dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among all patients with CKD, we recommend NOT administering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      except for short-term therapy (four weeks for one course only) of severe hyperphosphatemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other phosphate binders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/1\">",
"      Fournier A, Morini&egrave;re P, Ben Hamida F, et al. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992; 38:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/2\">",
"      Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/3\">",
"      Mucsi I, Hercz G. Control of serum phosphate in patients with renal failure--new approaches. Nephrol Dial Transplant 1998; 13:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/4\">",
"      Billa V, Zhong A, Bargman J, et al. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Dial Int 2000; 20:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/5\">",
"      Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/6\">",
"      Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/7\">",
"      Wahl P, Wolf M. FGF23 in chronic kidney disease. Adv Exp Med Biol 2012; 728:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/8\">",
"      Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/9\">",
"      Slatopolsky E, Robson AM, Elkan I, Bricker NS. Control of phosphate excretion in uremic man. J Clin Invest 1968; 47:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/10\">",
"      Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/11\">",
"      Friedman EA. Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int Suppl 2005; :S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/12\">",
"      Llach F. Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int Suppl 1990; 29:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/13\">",
"      Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/14\">",
"      Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/15\">",
"      Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/16\">",
"      Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/17\">",
"      Cofan F, Garc&iacute;a S, Combalia A, et al. Uremic tumoral calcinosis in patients receiving longterm hemodialysis therapy. J Rheumatol 1999; 26:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/18\">",
"      Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/19\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/20\">",
"      KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/21\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/22\">",
"      Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/23\">",
"      Dr&uuml;eke TB, Massy ZA. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol 2012; 23:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/24\">",
"      Isakova T, Guti&eacute;rrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/25\">",
"      Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 56:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/26\">",
"      Tangri N, Wagner M, Griffith JL, et al. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis 2011; 57:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/27\">",
"      Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/28\">",
"      Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/29\">",
"      Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/30\">",
"      Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/31\">",
"      Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/32\">",
"      Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial 2003; 16:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/33\">",
"      Marco MP, Craver L, Betriu A, et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; :S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/34\">",
"      Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/35\">",
"      Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/36\">",
"      Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/37\">",
"      Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003; 16:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/38\">",
"      Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009; 301:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/39\">",
"      Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/40\">",
"      Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/41\">",
"      Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/42\">",
"      Lafage MH, Combe C, Fournier A, Aparicio M. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992; 42:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/43\">",
"      Lafage-Proust MH, Combe C, Barthe N, Aparicio M. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab 1999; 84:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/44\">",
"      Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl 2004; :S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/45\">",
"      Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl 2005; :S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/46\">",
"      Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/47\">",
"      Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/48\">",
"      Slatopolsky E, Weerts C, Norwood K, et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/49\">",
"      Mai ML, Emmett M, Sheikh MS, et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/50\">",
"      Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/51\">",
"      Morini&egrave;re P, Djerad M, Boudailliez B, et al. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron 1992; 60:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/52\">",
"      Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/53\">",
"      Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/54\">",
"      Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/55\">",
"      Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103:e28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/56\">",
"      Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/57\">",
"      Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/58\">",
"      Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/59\">",
"      Hou SH, Zhao J, Ellman CF, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/60\">",
"      Weinreich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. Am J Kidney Dis 1995; 25:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/61\">",
"      Weinreich T, Ritz E, Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Perit Dial Int 1996; 16:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/62\">",
"      S&aacute;nchez C, L&oacute;pez-Barea F, S&aacute;nchez-Cabezudo J, et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/63\">",
"      Bro S, Brandi L, Daugaard H, Olgaard K. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize? Perit Dial Int 1997; 17:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/64\">",
"      Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/65\">",
"      Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/66\">",
"      Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/67\">",
"      Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/68\">",
"      Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/69\">",
"      Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/70\">",
"      Sadek T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003; 18:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/71\">",
"      Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial 2005; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/72\">",
"      Fischer D, Cline K, Plone MA, et al. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. Am J Kidney Dis 2006; 48:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/73\">",
"      Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/74\">",
"      Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/75\">",
"      Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/76\">",
"      Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/77\">",
"      Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/78\">",
"      Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/79\">",
"      St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/80\">",
"      Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/81\">",
"      Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/82\">",
"      Ferreira A, Fraz&atilde;o JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/83\">",
"      Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract 2008; 110:c273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/84\">",
"      Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/85\">",
"      Malluche HH, Siami GA, Swanepoel C, et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008; 70:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/86\">",
"      Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005; 67:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/87\">",
"      Kestenbaum B. Calcification in CKD: no closer to the cure. Am J Kidney Dis 2008; 51:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/88\">",
"      Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/89\">",
"      Manns B, Stevens L, Miskulin D, et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004; 66:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/90\">",
"      Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/91\">",
"      Joy MS, Finn WF, LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/92\">",
"      Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004; 19:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/93\">",
"      Finn WF, Joy MS, Hladik G, Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/94\">",
"      Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004; 13:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/95\">",
"      Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100:c8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/96\">",
"      Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005; 63:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/97\">",
"      Finn WF, SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/98\">",
"      Persy VP, Behets GJ, Bervoets AR, et al. Lanthanum: a safe phosphate binder. Semin Dial 2006; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/99\">",
"      Mehrotra R, Martin KJ, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008; 3:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/100\">",
"      D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; :S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/101\">",
"      Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005; 63:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/102\">",
"      Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/103\">",
"      Altmann P, Barnett ME, Finn WF, SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007; 71:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/104\">",
"      Behets GJ, Dams G, Vercauteren SR, et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004; 15:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/105\">",
"      Lacour B, Lucas A, Auch&egrave;re D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/106\">",
"      Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/107\">",
"      Aime S, Canavese C, Stratta P. Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate. Kidney Int 2007; 72:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/108\">",
"      Sprague SM, Abboud H, Qiu P, et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/109\">",
"      M&uuml;ller D, Mehling H, Otto B, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007; 2:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/110\">",
"      Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/111\">",
"      W&uuml;thrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/112\">",
"      Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/113\">",
"      Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/114\">",
"      Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci 1989; 297:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/57/33690/abstract/115\">",
"      Uribarri J. Acidosis in chronic renal insufficiency. Semin Dial 2000; 13:232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1942 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33690=[""].join("\n");
var outline_f32_57_33690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GUIDELINE TARGET LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      K/DOQI guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KDIGO guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GOAL SERUM PHOSPHATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phosphate restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Overview and choice of binder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Calcium salts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sevelamer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Lanthanum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Increased and/or extended hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      APPROACH TO HYPERPHOSPHATEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Stage 3 to 5 CKD not yet on dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      NOVEL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H998753883\">",
"      Nicotinamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H998753979\">",
"      Polynuclear iron (III)-oxyhydroxide phosphate (PA21)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CITRATE AND ALUMINUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stage 3 to 5 CKD not yet on dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1942|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/43/29373\" title=\"figure 1\">",
"      Relationship between GFR and PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/8/12429\" title=\"figure 2\">",
"      Citrate and aluminum absorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_57_33691="Causes of adrenal hyperandrogenism";
var content_f32_57_33691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of adrenal hyperandrogenism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary adrenal diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature adrenarche",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal tumors (adenomas, carcinomas, bilateral macronodular adrenal hyperplasia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &plusmn; Cushing syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &plusmn; Hyperaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Corticotropin (ACTH) hypersecretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticotropin-dependent Cushing's syndrome &plusmn; growth retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoid resistance &plusmn; hypermineralocorticoidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortisone reductase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hyperprolactinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Exogenous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androgens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental sulfatase deficiency (no hyperandrogenism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental aromatase deficiency (mother and female fetus virilization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P450 oxidoreductase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAPSS2 deficiency (apparent DHEA sulfotransferase deficiency)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33691=[""].join("\n");
var outline_f32_57_33691=null;
var title_f32_57_33692="DALM versus sporadic adenoma";
var content_f32_57_33692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical, pathological, and molecular features of ulcerative colitis-associated \"adenoma-like\" polypoid dyplastic lesions and sporadic adenomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        CUC-associated sporadic adenoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        CUC-associated polypoid dysplastic lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Clinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient age",
"       </td>",
"       <td>",
"        Older, &gt;50 years",
"       </td>",
"       <td>",
"        Younger, &lt;50 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disease activity",
"       </td>",
"       <td>",
"        Active or inactive",
"       </td>",
"       <td>",
"        Usually active",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disease duration",
"       </td>",
"       <td>",
"        Shorter, &lt;10 years",
"       </td>",
"       <td>",
"        Longer, &gt;10 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Pathological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &uarr; LP mononuclear cells",
"       </td>",
"       <td>",
"        Uncommon, &lt;20 percent",
"       </td>",
"       <td>",
"        Common, &gt;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &uarr; LP neutrophils",
"       </td>",
"       <td>",
"        Uncommon, &lt;40 percent",
"       </td>",
"       <td>",
"        Common, &gt;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tubulovillous/villous",
"       </td>",
"       <td>",
"        Uncommon, &lt;10 percent",
"       </td>",
"       <td>",
"        Occasional, &gt;10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Admixture",
"       </td>",
"       <td>",
"        Uncommon, &lt;20 percent",
"       </td>",
"       <td>",
"        Common, &gt;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Immunohistochemical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        p53",
"       </td>",
"       <td>",
"        Negative or weak",
"       </td>",
"       <td>",
"        Strong, diffuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta-catenin",
"       </td>",
"       <td>",
"        Strong, diffuse",
"       </td>",
"       <td>",
"        Negative, weak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Molecular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LOH for vHL (3p25)",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LOH for P16 (9p)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LOH for P53 (17q)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CUC: chronic ulcerative colitis; LP: lamina propria; Admixture: admixture of dysplastic and normal appearing crpyts at polyp surface; LOH: loss of heterozygosity.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the American College of Gastroenterology, (American Journal of Gastroenterology, 1997; 94:1746).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33692=[""].join("\n");
var outline_f32_57_33692=null;
var title_f32_57_33693="Severe asthma exacerbation in adults rapid overview";
var content_f32_57_33693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severe asthma exacerbation in adults: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical danger signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Use of accessory muscles of respiration; brief, fragmented speech; inability to lie supine; profound diaphoresis; agitation; severe symptoms that fail to improve with initial emergency department treatment",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Life-threatening airway obstruction can still occur when these signs are",
"         <strong>",
"          NOT",
"         </strong>",
"         present",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         <strong>",
"          Inability to maintain respiratory effort, cyanosis, and depressed mental status portend imminent respiratory arrest",
"         </strong>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measurement of expiratory airflow (peak expiratory flow rate or PEFR) is the best measure of severity; PEFR &lt;40 percent predicted (or &lt;200 L/minute in most adults) indicates severe obstruction; patients in severe distress are often unable to perform peak flow tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Severe hypoxemia",
"        </strong>",
"        (eg, SpO",
"        <sub>",
"         2",
"        </sub>",
"        &le;95 percent despite high flow O",
"        <sub>",
"         2",
"        </sub>",
"        treatment by nonrebreather mask)",
"        <strong>",
"         portends imminent respiratory arrest",
"        </strong>",
"        or possibly severe complication (eg, pneumothorax); continuous pulse oximetry monitoring should be performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial blood gas (ABG) evaluation does not assist management (unless reliable SpO",
"        <sub>",
"         2",
"        </sub>",
"        cannot be obtained) during the first few minutes if the patient is in extremis; ABG results can aid assessment if intubation is not an immediate concern; hypercapnia (a sign of impending respiratory failure) usually does not occur unless a PEFR &lt;25 percent of normal (generally &lt;100 to 150 L/min) is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph is generally unhelpful; obtain if complications suspected (eg, pneumonia, pneumothorax), diagnosis is in doubt, or patient is high-risk (eg, IV drug abuser, immunosuppressed, chronic pulmonary disease, heart failure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Standard treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Inhaled beta agonist:",
"        </strong>",
"        give",
"        <strong>",
"         albuterol",
"        </strong>",
"        2.5 to 5 mg every 20 minutes for three doses by nebulization, or 4 to 8 puffs every 20 minutes for up to four hours, properly administered, by metered dose inhaler (MDI) with spacer. Alternatively, for severe exacerbations, 10 to 15 mg can be administered by continuous nebulization over one hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxygen:",
"        </strong>",
"        give sufficient oxygen to maintain SpO",
"        <sub>",
"         2",
"        </sub>",
"        &ge;92 percent (&gt;95 percent in pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         IV:",
"        </strong>",
"        establish intravenous access; may give bolus of normal saline for prolonged episode to replace insensible losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ipratropium bromide:",
"        </strong>",
"        give 500 mcg by nebulization every 20 minutes for 3 doses, or 8 puffs by MDI with spacer every 20 minutes as needed for up to 3 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Systemic glucocorticoids:",
"        </strong>",
"        for patients with impending respiratory failure, give methylprednisolone 60 to 125 mg IV. For the majority of less severe asthma exacerbations, give prednisone 40 to 60 mg orally; alternatives include: dexamethasone 6 to 10 mg IV or hydrocortisone 150 to 200 mg IV; glucocorticoids may be given IM or orally if IV access is unavailable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Magnesium sulfate:",
"        </strong>",
"        give 2 g (8 mmol) IV over 20 minutes for life-threatening exacerbations and exacerbations that remain severe after one hour of intensive bronchodilator therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine: for patients suspected of having an anaphylactic reaction or unable to use inhaled bronchodilators for severe asthma exacerbation, give epinephrine 0.3 to 0.5 mg IM (eg, 0.3 to 0.5 mL of 1 mg/mL [also labeled 1:1000] solution); if severe asthma but no evidence of anaphylaxis, can give epinephrine 0.3 to 0.5 mg SC (eg, 0.3 to 0.5 mL of 1 mg/mL [also labeled 1:1000] solution); give epinephrine OR terbutaline but not both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terbutaline: may give 0.25 mg by SC injection every 20 minutes times 3 doses for severe asthma unresponsive to standard therapies; give terbutaline OR epinephrine but not both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endotracheal intubation and ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The decision to intubate during the first few minutes of a severe asthma attack is clinical. Slowing of the respiratory rate, depressed mental status, inability to maintain respiratory effort, or severe hypoxemia during an asthma exacerbation suggests the patient requires intubation. In the absence of anticipated intubation difficulty, rapid sequence intubation is preferred. Nasal intubation is not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The goal of mechanical ventilation is to maintain adequate oxygenation and ventilation while minimizing elevated airway pressures. This is accomplished by using high inspiratory flow rates (80 to 100 L/min), low tidal volumes (6 to 8 mL/kg), and low respiratory rates (10 to 14/minute). In some patients, elevations in PaCO",
"        <sub>",
"         2",
"        </sub>",
"        must be tolerated to avoid barotrauma (ie, permissive hypercapnia).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous; MDI: metered dose inhaler; PEFR: peak expiratory flow rate; SC: subcutaneous; SpO",
"     <sub>",
"      2",
"     </sub>",
"     : pulse oxygen saturation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33693=[""].join("\n");
var outline_f32_57_33693=null;
var title_f32_57_33694="Adverse effects for antipsychotic meds";
var content_f32_57_33694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F82533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F82533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected adverse effects of antipsychotic medications for schizophrenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight gain/diabetes mellitus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hyper-cholesterolemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        EPS/TD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prolactin elevation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sedation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anti-cholinergic side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Orthostatic hypotension",
"       </td>",
"       <td class=\"subtitle1\">",
"        QTc prolongation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        First generation agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlorpromazine",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluphenazine",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haloperidol",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loxapine",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perphenazine",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pimozide",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thioridazine*",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++++",
"       </td>",
"       <td class=\"centered\">",
"        ++++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thiothixene",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trifluoperazine",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Second generation agents",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aripiprazole",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asenapine",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clozapine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iloperidone",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lurasidone",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olanzapine",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paliperidone",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quetiapine",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Risperidone",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ziprasidone",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &minus;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Adverse effects may be dose dependent.",
"    <div class=\"footnotes\">",
"     EPS: extrapyramidal symptoms; TD: tardive dyskinesia; ND: no data.",
"     <br/>",
"     * Thioridazine is also associated with dose-dependent retinitis pigmentosa. Refer to text.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Clozapine also causes granulocytopenia or agranulocytosis in approximately 1 percent of patients requiring regular blood cell count monitoring.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Treatment Guidelines from The Medical Letter, August 2010; Vol.&nbsp;8 (96):61.",
"        <a href=\"file://www.medicalletter.org\">",
"         www.medicalletter.org",
"        </a>",
"        .",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33694=[""].join("\n");
var outline_f32_57_33694=null;
var title_f32_57_33695="Patch test control diagram";
var content_f32_57_33695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patch test control diagram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Petrolatum and Excipient control.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Elizabeth J Phillips.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_57_33695=[""].join("\n");
var outline_f32_57_33695=null;
             